



**Vaccines and Global Health: The Week in Review**  
**26 February 2022 :: Issue 646**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS  
Editor and  
Executive Director  
Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).

***Support this knowledge-sharing service:*** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

***Contents [click to move among sections]***

- :: Coronavirus [COVID-19] - WHO***
- :: Emergencies***
- :: Organization Announcements***
- :: Journal Watch***

## ***Milestones - Perspectives***

:::::

### **Remembering Dr. Paul Farmer**

*World-renowned infectious disease doctor, anthropologist, global health advocate, and author leaves large legacy*

Posted on Feb 21, 2022



Partners In Health announced that its founder, Dr. Paul Farmer, unexpectedly passed away today in Rwanda from an acute cardiac event while he was sleeping. Dr. Farmer was 62 years old. He is survived by his wife, Didi Bertrand Farmer, and their three children.

Partners In Health CEO Dr. Sheila Davis released the following statement: "Paul Farmer's loss is devastating, but his vision for the world will live on through Partners in Health. Paul taught all those around him the power of accompaniment, love for one another, and solidarity. Our deepest sympathies are with his family."

#### *About Dr. Paul Farmer*

Paul Farmer, M.D., Ph.D., was Kolokotrones University Professor and chair of the Department of Global Health and Social Medicine at Harvard Medical School, chief of the Division of Global Health Equity at Brigham and Women's Hospital in Boston, and co-founder and chief strategist of Partners In Health.

Dr. Farmer and his colleagues pioneered novel, community-based treatment strategies that demonstrate the delivery of high-quality health care in resource-poor settings. He wrote extensively on health, human rights, and the consequences of social inequality. Dr. Farmer was a member of the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences, from which he was the recipient of the 2018 Public Welfare Medal.

He authored multiple books, including: *In the Company of the Poor: Conversations with Dr. Paul Farmer and Fr. Gustavo Gutiérrez*, *Reimagining Global Health: An Introduction*, and *To Repair the World: Paul Farmer Speaks to the Next Generation*. His most recent book was released in November 2020: *Fevers, Feuds, and Diamonds: Ebola and the Ravages of History*.

:::::

:::::

### **Inequity 'a Moral Indictment of Our Times', Secretary-General Tells Universal Vaccination Debate, Saying It Gives COVID Free Reign to Circulate Unchecked**

Secretary-General *Statements and Messages*

25 February 2022 SG/SM/21159

*Following is the text of Secretary-General António Guterres' video remarks to the high-level thematic debate on "Galvanizing Momentum for Universal Vaccination", in New York today:*

Mr. President of the General Assembly, Excellencies, ladies and gentlemen,  
Let me begin by thanking the President of the General Assembly for convening this critical meeting focused on galvanizing momentum for universal vaccination.

We have the tools and the know-how to end the COVID-19 pandemic this year. But we have a long way to go. We are nowhere near meeting the WHO [World Health Organization] goal to vaccinate 70 per cent of people in all countries by the middle of this year.

**Yes, over 10 billion doses of COVID-19 vaccines have been administered globally. But this number masks the stark inequity in vaccine access. High-income countries have administered 13 times more doses per person than low-income countries. Eighty-five per cent of the people of Africa have not received a single vaccine dose.**

**This inequity is a moral indictment of our times.** It costs lives. It damages economies. And it gives the virus free reign to circulate unchecked and mutate, eroding hard-won gains and threatening the whole world.

Ending the pandemic requires ensuring access to tests, vaccines and treatments for everyone, everywhere. In recent months, deliveries of COVID-19 vaccines have been steadily increasing. This month marked COVAX's delivery of 1 billion doses to 92 low- and middle-income countries.

But much more is needed. **Galvanizing momentum means countries fulfilling and accelerating vaccine dose-sharing and donation commitments to COVAX with better quality of supply. It means manufacturers prioritizing and fulfilling vaccine contracts with COVAX, ensuring full transparency on monthly production and creating the conditions for the local or regional production of tests, vaccines and treatments.**

This includes pharmaceutical companies more rapidly sharing licences, know-how and technology. Regional production is critical for sustainable supply. It means significant investments in fragile health and economic infrastructure. It means donors and international financial institutions stepping up with the necessary support. **And it means fighting the plague of vaccine misinformation.**

We have seen hopeful progress when supply is secured and predictable ... when doses are donated with ample shelf-life ... and when there is a deep understanding of what a country needs to accelerate vaccinations.

Let's build on that momentum together. In the coming days, weeks and months let us use every opportunity — through the G20, the World Health Assembly, the G7 and the General Assembly — to mobilize ambitious action to meet the WHO vaccination strategy targets and ensure no one is left behind. If we do it right, we won't just end this pandemic, we will begin a truly meaningful effort to prevent future ones and build a safer, healthier world for all.

Thank you.

:::::

:::::

### **WHO Director-General as Guest Lecture at Robert S. McNamara Lecture on War and Peace, Harvard Kennedy School - 25 February 2022**

25 February 2022

*Speech [Excerpt]*

**...The authors of WHO's Constitution were well aware of the link between health and peace**, which is why they wrote in the preamble that the health of all peoples is fundamental to the attainment of peace and security, and is dependent upon the fullest co-operation of individuals and States.

Since those words were written, the world has faced many outbreaks and epidemics. Just this century, we have seen H5N1 influenza, SARS, MERS, the H1N1 pandemic, multiple Ebola outbreaks, Zika and more.

But of course, nothing matches the scale of the COVID-19 pandemic, which has thrown the world into turmoil for more than two years. **COVID-19 is a powerful demonstration that a pandemic is so much more than a health crisis. It illustrates the interconnectedness between health and the economy, security, education, and the intimate links between the health of humans, animals and our planet. There are many lessons to learn about what has worked and what has not. Let me suggest five:**

#### **The first is that science must guide policy, not the other way round.**

Throughout the pandemic, WHO has convened thousands of scientists from around the world to examine the rapidly emerging evidence and distil it into the guidance we give the world. Just this week, we have convened a research and innovation forum to identify the most pressing research priorities and chart the way forward.

Science has given us valuable insights into how this virus spreads, how it causes disease, and how to stop it. But in some countries and communities, and on social media, the marginalization and politicization of science has impeded the response to the pandemic and cost lives. Politics undermining science. My point is not that science should be the only consideration in decision-making about public health. My point is that science should be the central and guiding consideration.

#### **The second lesson is that science can in fact widen inequalities, unless it is paired with a commitment to equity.**

I'm sure that most or all of you are vaccinated. And yet as we speak, 83% of the population of Africa is yet to receive a single dose of vaccine. Vaccine nationalism, export bans and bilateral deals between manufacturers and high-income nations severely restricted the number of doses COVAX was able to ship in the first half of last year. The supply situation has now improved, and COVAX has been able to ship more than 1.2 billion doses of vaccine to 144 countries and territories.

WHO and our partners are working night and day to support countries to turn vaccines into vaccinations, to reach our target of vaccinating 70% of the population of every country by the middle of this year. To reach that target, we are calling on all countries to urgently fill the ACT Accelerator's financing gap of US\$16 billion, to ensure equitable access to vaccines, tests and treatments and PPE everywhere.

**The third lesson is that a resilient health system is not the same thing as an advanced medical care system.**

Even some countries with the most sophisticated medical care were overwhelmed by COVID-19. By contrast, some middle-income countries with fewer resources fared much better, thanks to investments in public health after outbreaks of SARS, MERS, H1N1 and others, especially in the Mekong region.

For instance, the simple art of contact tracing is one that many high-income countries have struggled with, but it's one that many low- and middle-income countries have done well, because of their experience with infectious disease outbreaks, and their investments in public health. The backbone of public health is robust primary health care, for detecting outbreaks at the earliest possible stage, as well as for preventing disease and promoting health at the community level.

**The fourth lesson is that the world needs a new agreement that sets the rules of the game for responding to epidemics and pandemics.**

Instead of a coherent and cohesive global response, the pandemic has been marked by a chaotic patchwork of responses, which in some cases have punished countries for doing the right thing, as in the case of the travel bans imposed on South Africa and Botswana when they first reported the emergence of the Omicron variant.

**And the fifth lesson is that trust is everything.**

A study published in *The Lancet* earlier this month examined the reasons why some countries have had higher rates of infection and death than others from COVID-19. The age profile of the country, GDP per capita, and mean body mass index were all found to play a part. But the researchers found that perhaps the single most important factor in countries' preparedness and ability to respond effectively is trust.

The study concluded that stronger risk communication and community engagement are essential for making the world safer against future epidemics and pandemics.

**Vaccines, diagnostics, therapeutics and other tools are essential, but the most effective tool is engaged and empowered communities...**



## **IFPMA - Three priorities to urgently increase access to COVID-19 vaccines**

25 February 2022

*[Excerpts]*

...Today, over 12 billion doses of vaccines have been produced, and more than 60 percent of the world's population have received at least one dose.[\[1\]](#) Getting as many people as possible vaccinated remains critical to our pandemic response. Even in the face of new variants, including most recently Omicron, current vaccines show continued protection from infection and significant effectiveness against hospitalization and death. For those people who do contract COVID-19 or are at-risk, several approved treatments are now an important and integral part of combatting COVID-19.

**Whilst significant progress has been made, COVID-19 vaccines are still not reaching equitably all priority populations worldwide.** In [May 2021](#), ...biopharmaceutical companies publicly committed to continue working with governments, international institutions, and non-governmental organizations to address vaccine inequity. Over the past six months, governments that have significant domestic supplies of COVID-19 vaccines have increasingly shared them with low- and lower-middle-income countries and vaccine manufacturers have continued to further ramp up production, including through voluntary licensing and technology transfer across several continents. By the end of January 2022, COVAX delivered its first billion vaccine doses.[\[2\]](#) In addition, over 3 billion doses have been delivered to low- and lower-middle-income countries. Moving forwards, we expect that a significant number of doses will continue to be delivered to low- and lower-middle-income countries.

**Our collective efforts are materializing, but to achieve an improvement in vaccine equity, manufacturers, governments, international institutions, and other non-governmental organizations must redouble efforts to support countries as they mobilize to execute national vaccine rollouts and remove barriers to the efficient distribution and administration of vaccine doses, so that they reach those who need them most.**

To support this endeavor,...**biopharmaceutical companies will continue to work with all relevant stakeholders on the following three overarching priorities and supporting activities:**

### **STEP UP SUPPORT FOR COUNTRY READINESS TO ROLL OUT COVID-19 VACCINE DOSES:**

- Work collaboratively with governments and established procurement mechanisms, such as COVAX and the African Vaccine Acquisition Trust (AVAT), to improve COVID-19 vaccine demand forecasting, alignment of deliveries and donations, distribution and administration, particularly in low- and lower-middle income countries;
- Continue engaging and sharing information with COVAX and other relevant organizations to ensure countries have better visibility of COVAX deliveries and donations;
- Provide timely information to assist with regulatory system streamlining and appropriate flexibilities to smooth the path for the reallocation of doses, and enable swift approval of new COVID-19 vaccines and manufacturing facilities;
- Continue to increase confidence in vaccines and vaccination programs, particularly by countering misinformation, providing timely vaccine effectiveness and safety data, and supporting adequate no-fault compensation programs;
- Continue to encourage governments to expand the number of vaccinators in countries to be able to rapidly deploy supply.

## **CONTRIBUTE TO EQUITABLE DISTRIBUTION OF COVID-19 VACCINE DOSES:**

- Continue to work with governments that have significant supplies of COVID-19 vaccines to improve dose sharing with low- and lower-middle-income countries in a responsible and timely way, through COVAX or other efficient established mechanisms such as AVAT;
- Expend every effort to make uncommitted COVID-19 vaccine doses available with urgency to prioritized populations in low- and lower-middle income countries through COVAX or other efficient established mechanisms;
- Work with relevant authorities to facilitate recognition of an extension to the COVID-19 vaccine shelf-life and batch-level extensions in line with ongoing studies looking at the stability of vaccines, to avoid vaccine wastage;
- Encourage the elimination of remaining trade and regulatory barriers to support cross-border supply and free flow of goods, raw materials, services, and personnel needed for COVID-19 vaccine manufacturing, distribution, and administration;
- Support efforts that tackle supply chain and logistic bottlenecks to increase vaccination rates.

## **CONTINUE TO DRIVE INNOVATION:**

- Continue to prioritize research to develop the next generation of COVID-19 vaccines that can provide long lasting and strong protection against variants of concern, and address logistical issues in storage, delivery, and administration;
- Urge governments to guarantee unhindered access to pathogens (samples and sequences) of any COVID-19 variants to support the rapid development of potential new vaccines and treatments;
- Continue to optimize production of vaccines, without compromising safety and quality, including through existing and additional voluntary collaborations with partners that can produce significant quantities.

:::::::  
:::::

## **WHO and NAM [National Academy of Medicine] encourage digital platforms to apply global principles for identifying credible sources of health information**

24 February 2022

The World Health Organization (WHO) and the National Academy of Medicine (NAM) are encouraging social media companies and other digital platforms to apply global principles for identifying credible sources of health information in their channels. The principles, originally published in a 2021 NAM paper, were evaluated by an international group of public health experts convened by WHO and BMJ in December 2021. The WHO meeting report is now available for download.

"Digital platforms have a uniquely powerful opportunity to enable worldwide access to high-quality health information," said NAM president Victor J. Dzau. "We hope these principles can serve as a launchpad for productive collaboration among industry, public health, and consumer representatives to protect and improve the health of people everywhere."

"The rapid spread of health misinformation through digital platforms has become a serious threat to public health globally," said Andy Pattison, Team Lead, Digital Channels, Department of Digital Health and Innovation, WHO. "Since the COVID-19 pandemic began, WHO has worked with technology companies to keep people safe and informed by improving accessibility of high-quality health information online. It is every platform's responsibility to protect the safety and health of their users. For this reason, we encourage all digital platforms to incorporate the new global principles for

identifying credible sources of health information in their guidelines, safety policies and enforcement to protect public health.”

**Table 1: Foundational Principles and Attributes of Credible Sources of Health Information**

Foundational Principle	Attributes
<b>Science-Based:</b> Sources should provide information that is consistent with the best scientific evidence available at the time and meet standards for the creation, review, and presentation of scientific content.	<ul style="list-style-type: none"> <li>Acknowledges the limitations and evolution of knowledge (e.g., early or incomplete knowledge, as seen in the COVID-19 pandemic; small sample size; correlation versus causation, etc.)</li> <li>Clearly labels information with the date it was last updated and strives to reassess and update content</li> <li>Demonstrates subject-specific expertise (i.e., consistent and well-regarded contributions in a given field)</li> <li>Links to and is linked to by other credible sources [a]</li> <li>Provides citations for information shared and evidence to justify claims</li> <li>Synthesizes information from multiple sources, rather than a single source</li> <li>Uses a consensus process to develop the information shared [b]</li> <li>Uses peer review or another form of content review to vet information before sharing [c]</li> </ul>
<b>Objective:</b> Sources should take steps to reduce the influence of financial and other forms of conflict of interest (COI) or bias that might compromise or be perceived to compromise the quality of the information they provide.	<ul style="list-style-type: none"> <li>Keeps health information separate from financial, political, or ideological messages</li> <li>Maintains independence from funders [d]</li> <li>Separates lobbying activities from health information (or does not engage in lobbying)</li> <li>Does not include advertisements with relevant health information (or does not host advertisements at all) [e]</li> </ul>
<b>Transparent and Accountable:</b> Sources should disclose the limitations of the information they provide, as well as conflicts of interest, content errors, or procedural missteps.	<ul style="list-style-type: none"> <li>Discloses financial and nonfinancial conflicts</li> <li>Discloses relevant policy positions and lobbying activities</li> <li>Follows FACA regulations or similar transparency policies [f]</li> <li>Posts public corrections or retractions</li> <li>Prioritizes accessibility and equitable access to information</li> <li>Provides a mechanism for public feedback</li> <li>Shares data, methods, or draft recommendations</li> </ul>

SOURCE: Kington, R., S. Arnesen, W-Y. S. Chou, S. Curry, D. Lazer, and A. Villarruel. 2021. Identifying Credible Sources of Health Information in Social Media: Principles and Attributes. *NAM Perspectives*. Discussion Paper, National Academy of Medicine, Washington, DC. <https://doi.org/10.31478/202107a>

NOTES:

- For example, an organization could seek public comments on an interim set of health guidelines before finalizing and sharing the information more broadly.
- A consensus process involves assembling a group of experts with diverse perspectives who assess a body of evidence and deliberate in order to arrive at an opinion or guidance that reflects the consensus of the group.
- A peer review process involves sharing the draft of a publication or other product with reviewers who have expertise or experience in the given topic and can provide feedback as to the product's accuracy, balance, and appropriateness.
- For example, an academic journal could maintain editorial independence (i.e. sole authority over published content) from the organization that funds it.
- For example, an organization might host an advertisement for a cancer drug but keep this advertisement separate from the information it shares about cancer.
- FACA stands for the Federal Advisory Committee Act, which established requirements for committees that advise the federal government. These requirements include public access to meetings and meeting notes, as well as summaries of expenditures (<https://www.gsa.gov/policy-regulations/policy/federal-advisory-committee-management/advice-and-guidance/the-federal-advisory-committee-act-faca-brochure>)

The principles state that, to be considered credible, sources should be science-based, objective, transparent, and accountable. The NAM paper provides a [list of material attributes](#) that platforms and consumers can use to assess a source's alignment with these principles.

Participants at the December 2021 WHO meeting agreed that the principles and attributes are generally applicable to global contexts. However, they identified potential implementation challenges, noting that "factors such as culture, language, the influence of the source of information and political views within the country can affect what is seen as credible."...

:::::  
:::::

**World Economic Forum** [to 26 Feb 2022]

<https://agenda.weforum.org/news/>

*Media [Selected]*

**[Public Thinks COVID-19 Is Here to Stay, Global Survey Finds](#)**

News 24 Feb 2022

- Most adults surveyed across 30 countries agree that even if maximum measures were to be maintained COVID-19 will never be fully eradicated
- However, support for mandatory vaccination or proof of vaccination in certain public locations varies wildly across different regions and countries
- Generally, Asian and Latin American countries are the most supportive of maintaining vaccine mandates, while Eastern and Central Europe and the United States were the most opposed
- Read more about the World Economic Forum-Ipsos Global Survey on COVID-19 Expectations and Vaccination [here](#)

A new Ipsos survey for the [World Economic Forum](#) finds that, on average across 30 countries, 71% of adults do not expect that COVID-19 will ever stop spreading entirely. A majority of adults in every country – from 51% in China to 85% in the Netherlands – agree that "even with all the measures being taken, we will never be able to fully stop the spread of COVID-19 and variants."

However, the survey reveals vastly different levels of popular support for mandatory vaccination across countries. In India, China, Malaysia, Singapore, and throughout Latin America, more than 75% support "making a COVID-19 vaccine mandatory for anyone eligible to receive one." In most of Central and Eastern Europe as well as in the United States, majorities are opposed to it. Views about requiring proof of vaccination to be allowed in various facilities (e.g., sporting venues, restaurants, workplaces) mirror those on mandatory vaccination and vary similarly across countries.

Over the past year, support for vaccination mandates has grown significantly in China, Italy, Australia, Germany, and France, but it has decreased in Japan and the U.S.

These are the main findings of a survey of 20,525 adults aged 18-74 from 30 countries conducted by Ipsos on its [Global Advisor online platform](#) between January 21 and February 4, 2022...

*...Support for mandatory COVID-19 vaccination*


On average across all 30 countries surveyed, 63% support "making a COVID-19 vaccine mandatory for anyone eligible for it" while 32% oppose it and 5% don't know. Support exceeds 75% in emerging countries of Asia and Latin America, led by India (89%) Peru (86%). In contrast, opposition dominates

in Romania (57%), Hungary (54%), Russia (53%), the United States (51%), and the Netherlands (51%).

## Opinion on “making a COVID-19 vaccine mandatory for anyone eligible to receive one”



■ Support ■ Don't know ■ Oppose



Survey was conducted between Friday, January 21, and Friday, February 4, 2022, on Ipsos' Global Advisor online survey platform among 20,525 adults aged 18-74 in the United States, Canada, Malaysia, South Africa, and Turkey, 21-74 in Singapore, and 16-74 in all 24 other countries.

Chart: Ipsos • Source: [Global Advisor](#) • [Embed](#) • Created with [Datawrapper](#)



## Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### Weekly Epidemiological and Operational updates

Last update: 25 Feb 2022


**Confirmed cases ::** 430 257 564

**Confirmed deaths ::** 5 922 049

**Vaccine doses administered:** 10 407 359 583



**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 20 February 2022\*\***



\*\*See [Annex 2: Data, table, and figure notes](#)

### Weekly epidemiological update on COVID-19 - 22 February 2022

#### Overview

Globally, during the week of 14 to 20 February 2022, the number of new COVID-19 cases and deaths decreased by 21% and 8% respectively, compared to the previous week. Across the six WHO regions, over 12 million new cases and over 67 000 new deaths were reported. As of 20 February 2022, over 422 million confirmed cases and over 5.8 million deaths have been reported globally.

At the regional level, the Western Pacific Region reported a 29% increase in the number of new weekly cases while all other regions reported decreases. The number of new weekly deaths increased in the Western Pacific (+21%) and the African (+20%) regions, and decreased in the South-East Asia (-37%), the Regions of the Americas (-9%), the European (-5%) and Eastern Mediterranean regions (-4%).

In this edition we provide an update on:

The geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the prevalence and summary of current evidence of the Omicron variant. We also provide updates on vaccine effectiveness for the Delta and Omicron variants.

::::::

### **Statement on Omicron sublineage BA.2**

WHO 22 February 2022

As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution ([TAG-VE](#)) met yesterday to discuss the latest evidence on the Omicron variant of concern, including its sublineages BA.1 and BA.2.

Based on available data of transmission, severity, reinfection, diagnostics, therapeutics and impacts of vaccines, **the group reinforced that the BA.2 sublineage should continue to be considered a variant of concern and that it should remain classified as Omicron**. The group emphasized that BA.2 should continue to be monitored as a distinct sublineage of Omicron by public health authorities.

The Omicron variant of concern is currently the dominant variant circulating globally, accounting for nearly all sequences reported to GISAID. Omicron is made up of several sublineages, each of them being monitored by WHO and partners. Of them, the most common ones are BA.1, BA.1.1 (or Nextstrain clade 21K) and BA.2 (or Nextstrain clade 21L). At a global level, the proportion of reported sequences designated BA.2 has been increasing relative to BA.1 in recent weeks, however the global circulation of all variants is reportedly declining.

BA.2 differs from BA.1 in its genetic sequence, including some amino acid differences in the spike protein and other proteins. Studies have shown that BA.2 has a growth advantage over BA.1. **Studies are ongoing to understand the reasons for this growth advantage, but initial data suggest that BA.2 appears inherently more transmissible than BA.1, which currently remains the most common Omicron sublineage reported.** This difference in transmissibility appears to be much smaller than, for example, the difference between BA.1 and Delta. Further, although BA.2 sequences are increasing in proportion relative to other Omicron sublineages (BA.1 and BA.1.1), there is still a reported decline in overall cases globally...

::::::

### **WHO Director General Speeches [selected]**

<https://www.who.int/director-general/speeches>

*Selected*

25 February 2022

Speech

**[WHO Director-General as Guest Lecture at Robert S. McNamara Lecture on War and Peace, Harvard Kennedy School - 25 February 2022](#)**

*[See Perspectives above for excerpt]*

25 February 2022

Speech

**WHO Director-General's opening remarks at High-Level Thematic Debate: Galvanizing Momentum for Universal Vaccination, President of the 76th Session of the General Assembly - 25 February 2022**

24 February 2022

Speech

**WHO Director-General's opening remarks at COVID-19 Global research & innovation forum – 24 February 2022**

24 February 2022

Speech

**WHO Director-General's opening remarks at first meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response – 24 February 2022**

[Excerpt]

...This is a momentous undertaking, and a necessary one. Because the COVID-19 pandemic has shown that the status quo is not good enough to protect our communities, our societies, and our economies.

The pandemic has exposed and exacerbated fundamental weaknesses in pandemic preparedness and response at both the national and the global levels:

- :: Complex and fragmented governance and lack of leadership;
- :: Inadequate financing;
- :: And insufficient systems and tools.

Instead of solidarity, the pandemic has been marred by inequity.

**Equity does not mean providing access to tools when there is a surplus, when the privileged have used what they need. It is about timely access, so that all people have access to all the available tools, at the same time.**

**The lack of trust or the trust deficit between and within countries, partners and stakeholders has shattered our unified defence during the pandemic. Voluntary mechanisms have not solved and will not solve these challenges.**

Global health security is too important to be left to chance, or goodwill, or shifting geopolitical currents, or the vested interests of companies and shareholders. Recognizing that our fates as a global community are intertwined, the World Health Assembly established this intergovernmental negotiating body during a special session, which, by the way, is only the second time it had held such an extraordinary meeting.

**Today's meeting is the start of an historic opportunity for Member States to work together to strengthen the world's structures and systems for pandemic preparedness and response.**

While we are operating under an ambitious timeline, we need to take the lessons learned from the COVID-19 pandemic and use them to build back better. **The aim should be a world better prepared to prevent pandemic threats and respond to them when they do occur, in at least five ways:**

**First**, by building national, regional and global capacities for preparing and responding to pandemics and other global health emergencies, based on a whole-of-government and whole-of-society approach;

**Second**, by establishing global access and benefit sharing for all pathogens, and determining a global policy for the equitable production and distribution of countermeasures;

**Third**, by establishing robust systems and tools for pandemic preparedness and response;

**Fourth**, by building a long-term plan for sustainable financing, so that support for global health threat management and response systems is shared by all;

**And fifth**, by empowering WHO to fulfil its mandate as the directing and coordinating authority on international health work, including for pandemic preparedness and response

At the Special Session, the World Health Assembly specifically noted the importance of broad engagement to ensure a successful outcome. So we encourage all Member States to participate in this process and support the work of the INB, in developing a new international instrument on pandemic prevention, preparedness and response.

Now begins the critical process of coming together around a common goal – health – for the future of our children and their children.

Together, let us chart a way forward, for this and future generations, to better prevent, prepare and respond to future pandemics and health emergencies.

23 February 2022

Speech

[\*\*WHO Director-General's remarks at the Preparatory Meeting of the Global Fund's Seventh Replenishment – 23 February 2022\*\*](#)

23 February 2022

Speech

[\*\*WHO Director-General's opening remarks at the media briefing on COVID-19 – 23 February 2022\*\*](#)

22 February 2022

Speech

[\*\*WHO Director-General's remarks at ILO Multisectoral Policy Forum: "Building a human-centered recovery from the COVID-19 crisis" - 22 February 2022\*\*](#)

::::::

::::::

[\*\*Status of COVID-19 Vaccines within WHO EUL/PO evaluation process 23 December 2021\*\*](#)

*[Full scale view available at title link above]*

*[Updated on 18 February 2022]*

::::::

## **COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements**

*[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]*

### **AstraZeneca**

Press Releases - *No new digest announcements identified*

### **Bharat Biotech**

Press Releases - *No new digest announcements identified*

### **BioCubaFarma** – Cuba

Últimas Noticias - *Website not leading at inquiry*

### **Biontech**

Press Releases

**Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union**

24 February 202

### **CanSinoBIO**

News - *[Website not responding at inquiry]*

### **Clover Biopharmaceuticals** - China

News - *No new digest announcements identified*

### **Curevac [Bayer Ag – Germany]**

News - *Website not responding at inquiry*

### **Gamaleya National Center**

Latest News and Events - *See Russia below*

### **IMBCAMS**, China

Home - *Website not responding at inquiry*

### **Janssen/JNJ**

Press Releases - *No new digest announcements identified*

### **Moderna**

Press Releases

February 24, 2022

**EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union**

February 23, 2022

**Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration**

*Agreement to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies*

February 22, 2022

**Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data**

**Novavax**

Press Releases

**Novavax Announces Shipments of its COVID-19 Vaccine to European Union Member States**

Feb 23, 2022

**Pfizer**

Recent Press Releases

02.24.2022

**Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union**

02.23.2022

**CDC Advisory Committee on Immunization Practices Votes to Recommend TicoVac™, Pfizer's Tick-Borne Encephalitis (TBE) Vaccine, For Those at Risk of Virus Exposure**

**Sanofi Pasteur**

Press Releases

February 23 2022

Press releases

**Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine**

- \* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus)
- \* In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated:
  - \* 100% efficacy against severe COVID-19 disease and hospitalizations
  - \* 75% efficacy against moderate or severe COVID-19 disease
  - \* 57.9% efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today's environment dominated by variants of concern
- \* Favorable safety profile following both primary series and booster vaccinations

**Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

**Shifa Pharmed [Iran]**

<http://shafapharmed.com/>

No news page identified.

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified

**Sinovac**

Press Releases - No new digest announcements identified

**Vector State Research Centre of Virology and Biotechnology**

Home - No new digest announcements identified

**Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

::::::

**GSK**

Press releases for media

**[Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine](#)**

24 February 2022 Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for *COVIFENZ®*, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 to 64 years of age...

**[23 February 2022 Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine](#)****Merck**

News releases - No new digest announcements identified

**Novartis**

News - No new digest announcements identified

**SK Biosciences**

Press releases - No new digest announcements identified

**Valneva**

Press Releases

February 25, 2022

**[Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001](#)**

February 21, 2022

**[Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development](#)**

::::::

::::::

**[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 26 Feb 2022](#)**


An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



### **COVID-19 Global Targets and Progress Tracker - IMF**

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.


#### **Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)**



::::::

## Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>



::::::

::::::

## Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 26 Feb 2022]: <https://data.undp.org/vaccine-equity/>  
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



::::::

::::::

## Duke – Launch and Scale Speedometer


[The Race for Global COVID-19 Vaccine Equity](#)

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)



Data updated on Feb 25th 2022



## COVID Vaccines – OCHA:: HDX

### [COVID-19 Data Explorer: Global Humanitarian Operations](#)

#### **COVID-19 Vaccine Roll-out**

**26 Feb 2022** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 430M total confirmed cases; 5.9M total confirmed deaths**

**Global vaccines administered: 10.6B**

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 260M

Other Delivered (Number of Doses): 250M

Total Delivered (Number of Doses): 510M

Total Administered (Number of Doses): 310M

::::::

::::::



### **Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **26 Feb 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).





::::::

::::::

### ***Our World in Data***

[Coronavirus \(COVID-19\) Vaccinations](#) [Accessed 26 Feb 2022]

- **62.6%** of the world population has received at least one dose of a COVID-19 vaccine. **10.68 billion doses** have been administered globally, and **29.51 million** are now administered each day.
- Only **12.3%** of people in low-income countries have received at least one dose.



:::::  
:::::

## **U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **HHS**

News

#### **Readout of Secretary Becerra's Virtual Roundtable on Increasing Routine Vaccinations**

February 24, 2022 | News Release

#### **BARDA – U.S. Department of HHS** [to 26 Feb 2022]

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

News

*No new digest content identified.*

:::::

### **FDA**

Press Announcements

*No new digest content identified.*

#### **Vaccines and Related Biological Products Advisory Committee- FDA**

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

Calendar

#### **Vaccines and Related Biological Products Advisory Committee March 3, 2022 Meeting Announcement - 03/03/2022**

... The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2022 – 2023 influenza season...

:::::

#### **White House [U.S.]** [to 26 Feb 2022]

Briefing Room – Selected Major COVID Announcements

#### **FACT SHEET: Administration Announces New Actions to Address the Needs of People with Disabilities and Older Adults in Response to and Recovery from COVID-19**

February 24, 2022 • Statements and Releases

#### **U.S. Department of State** [to 26 Feb 2022]

<https://www.state.gov/coronavirus/releases/>

Media Notes

*No new digest content identified.*

#### **USAID** [to 26 Feb 2022]

<https://www.usaid.gov/news-information/press-releases/2021>

Selected Press Releases, Statements, Announcements

News

#### **New General License 20 Authorizing Certain Afghanistan Transactions**

February 25, 2022

USAID welcomes the announcement by the Department of the Treasury's Office of Foreign Assets Control (OFAC) that it is expanding authorizations for commercial and financial transactions in Afghanistan, including with its governing institutions. The issuance of General License (GL) 20 aims to ensure that U.S. sanctions do not prevent or inhibit the transactions and activities needed to support the basic human needs of the people of Afghanistan, and underscores the United States' commitment to working with the private sector, international partners and allies, and international organizations to support the people of Afghanistan.

### **On Russia's Unprovoked and Unjustified Attack on Ukraine**

February 25, 2022

After months of relentless diplomacy in which the United States, Ukraine and our allies engaged with Russia in good faith to avoid further conflict, President Putin has shown he is not interested in peace, but only in power—in invading a neighbor in a premeditated and unprovoked attack, carving up sovereign territory by force, and denying the Ukrainian people the right to live in peace and determine their own future. He has gone so far as to suggest Ukraine has no ability to exist as a nation separate from Russia, and baselessly and debasingly invoked claims of genocide to create a pretext for this war of choice—a war for which Russia is entirely responsible.

### **USAID Providing Humanitarian Assistance in Response to Devastating Floods in Petrópolis, Brazil**

February 24, 2022

The U.S. Agency for International Development (USAID) is providing \$100,000 in immediate humanitarian assistance to support people affected by severe flooding and landslides following an intense storm in Brazil's Petrópolis city, Rio de Janeiro State. The devastating storm generated more rain in a single afternoon than the historical average for the entire month. The fatal floods have affected thousands of people across the city, displacing at least 3,000 people, and destroying homes.

:::::  
:::::

### **Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

#### **European Medicines Agency**

[News & Press Releases](#)

#### **[News: Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 21-24 February 2022 \(new\)](#)**

CHMP, Last updated: 25/02/2022

#### **[News: EMA recommends authorisation of booster doses of Comirnaty from 12 years of age \(new\)](#)**

CHMP, Last updated: 24/02/2022

#### **[News: EMA recommends approval of Spikevax for children aged 6 to 11 \(new\)](#)**

CHMP, PDCO, Last updated: 24/02/2022

:::::

**European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*Latest Updates [Selected]*

*No new digest content identified.*

::::::



**European Centre for Disease Prevention and Control**

COVID-19 Vaccine Tracker

Cumulative vaccine uptake (%) in the total population in EU/EEA countries

At least one dose	Primary course	Booster/additional dose
75.0%	71.7%	50.9%

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-02-25

*Accessed 26 Feb 2022*

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

::::::

**European Commission**

<https://ec.europa.eu/commission/presscorner/home/en>

*Statement 25 February 2022*

**[World Rare Disease Day: Statement by Commissioner Stella Kyriakides](#)**

Today, more than 6,000 rare diseases are affecting up to 36 million people in the EU. For those living with rare diseases – many of them children - quality of life is strongly affected, as they often cause chronic pain and suffering, and some can be life-threatening.

::::::

::::::

**Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**




## Africa CDC Vaccine Dashboard

### Africa Vaccinated

Vaccine Administered (Total)	(60.85% of supply)
Partially Vaccinated	(17.47% of population)
Vaccination Completed	(12.33% of population)
Booster Dose	(0.91% of population)

### Total of Supply Administered



Vaccines received from COVAX

**51**  
Countries

Vaccines received bilaterally

**52**  
Countries

Vaccines received from AVATI

**38**  
Countries

Accessed 26 Feb 2022. Full scale, interactive dashboard available at:  
<https://africacdc.org/covid-19-vaccination/>

:::::::  
:::::::

## Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

### Kazakhstan becomes the first country outside Russia to authorize Sputnik M vaccine for adolescents

Press release, 22.02.2022

### Sputnik Light can become a major booster for those vaccinated with inactivated Chinese COVID vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters

Press release, 21.02.2022

:::::  
:::::

## India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :  
26 February 2022, 08:00  
IST (GMT+5:30)

(↑↓ Status change since  
yesterday)

Active (0.28%)

121881 (12354↓)

Discharged (98.52%)

42270482 (23598↑)

Deaths (1.20%)

513481 (255↑)

COVID-19 Vaccination  
as on : 26 February  
2022, 08:00 IST  
(GMT+5:30)

Total Vaccination : 1,77,17,68,379 (28,29,582↑)

## Government of India – Press Information Bureau

*Latest Press Releases*

### [COVID - 19 Vaccination Update - Day 407](#)

- :: India's cumulative vaccination coverage over 177.40Crore
- :: More than 21 lakh Vaccine doses administered today till 7 pm

*Posted On: 26 FEB 2022 8:06PM by PIB Delhi*

## Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

*Press Releases*

*No new digest content identified.*

:::::  
:::::

## China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### National Health Commission of the People's Republic of China [to 26 Feb 2022]

<http://en.nhc.gov.cn/>

*News*

### [Feb 26: Daily briefing on novel coronavirus cases in China](#)

On Feb 25, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 249 new cases of confirmed infections.

### [China widens choices for COVID-19 booster shots](#)

Updated: 2022-02-21 | CHINA DAILY

China began delivering COVID-19 booster shots over the weekend based on technologies different from those used in initial inoculations in the country, in an effort to reinforce herd immunity against the disease.

The method, known as sequential immunization, targets people over 18 years old who are fully vaccinated with one of the three inactivated vaccines produced by Sinopharm and Sinovac Biotech, according to the National Health Commission. Two shots are required for full vaccination.

Instead of receiving an additional shot developed with the same technology, which has been standard practice in the country since October, people eligible for a booster now have wider choices. They can get a protein subunit COVID-19 vaccine made by Anhui Zhifei Longcom Biopharmaceutical or a viral vector vaccine from CanSino Biologics.

Protein subunit vaccines use a subunit of virus antigen to trigger an immune response, and viral vector vaccines use a modified version of a different virus to instruct our cells to fight the virus, according to Chinese researchers.

"Research has shown that boosters of both the same and different technologies are effective at further improving protection against the disease," Wu Liangyou, deputy director of the commission's Bureau of Disease Prevention and Control, said at a briefing on Saturday. "The public only needs to select one of them."...

## **Second medical team from mainland arrives in Hong Kong in fighting latest COVID-19 outbreak**

2022-02-21

HONG KONG - The second team of mainland health experts and workers arrived in the Hong Kong Special Administrative Region (HKSAR) via the Shenzhen Bay Port on Saturday to work with the HKSAR government in fighting the latest COVID-19 outbreak.

The team is comprised of 114 members, including four critical care medical specialists, four administrative staff members, and 106 sampling workers.

The four critical care specialists will discuss with clinical medical experts in Hong Kong on the treatment of severe and critical COVID-19 cases, and share the treatment experience of COVID-19 patients in the mainland.

Also on Saturday, the construction of two community isolation and treatment facilities built with assistance from the mainland began at Penny's Bay and Kai Tak Pier in Hong Kong, respectively. Designed and constructed by China State Construction International Holdings Ltd, the two isolation facilities are expected to provide about 9,500 quarantine units when fully operational....

:::::  
:::::  
:::::

## ***Emergencies***

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*  
<https://polioeradication.org/polio-today/polio-now/this-week/>

### **Polio this week as of 23 February 2022**

:: • After the safe and successful rollout of nationwide polio campaigns since November 2021, we have received **tragic news that 8 health workers at the forefront have been killed this morning in a series of shootings in Takhar and Kunduz in northeast Afghanistan. The vaccination**

**campaign has been suspended in both provinces.** A statement has been issued by the Regional Director of WHO's Eastern Mediterranean Region, Dr Ahmed Al-Mandhari, as well as by the United Nations in the country, condemning these attacks, expressing condolences to the families and underscoring that the provision of health and the safety of health workers at the forefront are paramount, and must be kept neutral to any geo-political situation anywhere. Our thoughts and prayers are both with the families and our teams on the ground at this time.

:: Last week, Malawi reported a WPV1 case in a 3-year-old girl in the capital, Lilongwe. Analysis shows that the virus is genetically linked to WPV1 that was detected in Pakistan's Sindh province in October 2019. This is the first WPV1 case from the continent of Africa in over five years. [Read more...](#)

*Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):*

- **DR Congo:** two cVDPV2 cases
- **Madagascar:** two cVDPV1 cases and six cVDPV1 positive environmental samples
- **Malawi:** one WPV1 case
- **Nigeria:** three cVDPV2 cases and eight positive environmental samples
- **Yemen:** three cVDPV2 cases

:::::  
:::::

### **Disease Outbreak News (DONs)**

:: [Lassa Fever – United Kingdom of Great Britain and Northern Ireland](#)

21 February 2022

On 9 February 2022, WHO was notified by the United Kingdom health authorities of two laboratory confirmed cases and one probable case of Lassa fever. As of 18 February, three cases have been confirmed and one death has been reported. These are the first reported Lassa fever cases in the United Kingdom since 2009, and represents the second known case of secondary transmission of Lassa fever in Europe.

The first case travelled to Mali in late 2021, where Lassa fever is endemic. After returning to the United Kingdom, the individual developed symptoms of fever, fatigue and loose stool, and was subsequently hospitalized. The first case has now recovered. The second and third cases were family members of the first case and did not travel to Mali. Both were admitted to the hospital and the third case has sadly died...

:::::  
:::::

### **WHO/OCHA Emergencies**

#### **Health emergencies list - WHO**

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Afghanistan crisis](#) [Last apparent update: 17 Jan 2022]

[Crisis in Northern Ethiopia](#) [Last apparent update: 1 June 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) [Last apparent update: 17 Aug 2021]

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) [Last apparent update: 17 Aug 2021]

[Coronavirus disease \(COVID-19\) pandemic](#) [See COVID above]

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) [Last apparent update: 24 July 2018]

[Yemen crisis](#) [Last apparent update: 12 February 2021]

[Syria crisis](#) [Last apparent update: 18 June 2021]

[Somalia crisis](#) [Last apparent update: 24 March 2018]

[Nigeria crisis](#) [Last apparent update: 1 Oct 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) [Last apparent update: 17 Aug 2021]

[Zika virus disease outbreak, 2015-2016](#) [Last apparent update: 24 Jan 2020]

[Ebola outbreak: West Africa, 2014-2016](#) [Last apparent update: 17 Aug 2021]

[Iraq crisis](#) [Last apparent update: 9 Jan 2008]

[South Sudan crisis](#) [Last apparent update: 23 Sep 2020]

[Avian influenza A \(H7N9\) virus outbreak](#) [Last apparent update: 13 September 2021]

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) [Last apparent update: 8 July 2019]

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

::::::

[UN OCHA – Current Emergencies](#)

*Current Corporate Emergencies*

[Afghanistan](#)

*No new updates identified.*

[Northern Ethiopia](#)

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 24 February 2022](#)

*HIGHLIGHTS*

- Regional authorities estimate few hundred thousand people displaced in Zone 2 in Afar, while displacement is still ongoing, significantly increasing the needs in the region.
- More than 6.8 million people reached with food assistance in Amhara under the current food distribution cycle launched two months ago.
- About 4 MT of seeds distributed to more than 11,000 farming households in Tigray since the start of the year.
- More than 1,500 children, including more than 630 girls, in 13 schools in Dubti and Awash Fentale woredas in Afar enrolled in informal learning programs.
- Humanitarian partners continue to reduce their operations in Tigray due to lack of supplies, fuel, and cash.

:::::::  
::::::

**WHO & Regional Offices** [to 26 Feb 2022]

<https://www.who.int/>

*News [Selected]*

25 February 2022

News release

**Recommendations announced for influenza vaccine composition for the 2022-2023 northern hemisphere influenza season**

24 February 2022

Statement

**WHO Director-General: Deeply concerned over escalating health crisis in Ukraine**

24 February 2022

Departmental news

**WHO and NAM encourage digital platforms to apply global principles for identifying credible sources of health information**

*[See Perspectives above for detail]*

23 February 2022

Departmental news

**ILO-WHO step up collaboration to address health emergencies and promote healthier and safer working populations**

23 February 2022

News release

**Moving forward on goal to boost local pharmaceutical production, WHO establishes global biomanufacturing training hub in Republic of Korea**

22 February 2022

Statement

**Statement on Omicron sublineage BA.2**

*[See COVID above for detail]*

22 February 2022

Departmental news

## **[WHO launches new guideline for the control and elimination of human schistosomiasis](#)**

21 February 2022

Departmental news

## **[The Vaccine Manufacturing Workshop for South-East Asia and Western Pacific Regions ended](#)**

21 February 2022

Joint News Release

## **[New WHO/ILO guide urges greater safeguards to protect health workers](#)**

21 February 2022

Departmental news

## **[WHO validates Saudi Arabia for eliminating trachoma as a public health problem](#)**

::::::

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

#### **WHO African Region**

:: [New push to drive up Africa's COVID-19 vaccination](#)

24 February 2022 Brazzaville – One year since the COVAX Facility delivered the first COVID-19 vaccines to Africa, around 400 million doses have been administered – the region's largest ever vaccine rollout in a single year. However, vaccination rates in the continent are the lowest in the world. To help bolster uptake, World Health Organization (WHO), UNICEF, Gavi, the Vaccine Alliance, and partners are supporting mass vaccination campaigns in 10 priority countries to reach 100 million people by the end of April 2022.

:: [Mauritius' strong COVID-19 vaccination drive reaches 76% of population](#) 25 February 2022

:: [Ramping up COVID-19 vaccination among Kenya's hard-to-reach communities](#) 22 February 2022

#### **WHO Region of the Americas PAHO**

:: [PAHO Urges Increased Polio Vaccination of Children in the Americas](#)

23 Feb 2022 Only 82% of children received a third dose of polio vaccine in 2020, the lowest rate since 1994 Washington, DC, February 23, 2022 (PAHO)- The Pan American Health Organization (PAHO) is calling on the countries of the Americas to redouble efforts to vaccinate children against polio. The vaccination rate with all three doses of the polio...

:: [Low vaccination rates in the Caribbean must be urgently addressed to stop the spread of COVID-19 says PAHO Director](#)

23 Feb 2022 10 out of 13 countries and territories in the Americas yet to reach 40% coverage are in the Caribbean but the tide can still be turned with targeted interventions Washington D.C. 23 February 2022 (PAHO) – Low vaccination coverage in many countries of the Caribbean must be urgently addressed to stop the spread of COVID-19 and protect the most...

#### **WHO South-East Asia Region SEARO**

*No new digest content identified*

#### **WHO European Region EURO**

:: [WHO/Europe Statement on Ukraine \(24 February 2022\)](#) 24-02-2022

### **WHO Eastern Mediterranean Region EMRO**

:: [COVID-19 triggers critical care and ICU capacity-building by WHO in fragile, conflict-affected and vulnerable countries](#) 24 February 2022

:: [WHO and IsDB in Yemen: ensuring treatment for children with genetic blood disorders](#) 23 February 2022

:: [Somalia hosts first ever health research conference in Garowe](#) 20 February 2022

### **WHO Western Pacific Region**

*No new digest content identified*

::::::

### **WHO Events**

<https://www.who.int/news-room/events/2>

*[Selected]*

#### **9th ACT-Accelerator Facilitation Council meeting**

28 February 2022 12:30 – 15:00 CET

*Primary Objectives*

:: To take stock of progress to meet global COVID-19 targets for vaccines, tests, treatments and PPE

:: Share country experience, lessons learnt and progress in meeting global COVID-19 targets

:: Reinforce Facilitation Council commitment and political support for the ACT-Accelerator campaign

#### **Expanding our understanding of post COVID-19 condition web series: Neurology and Mental Health**

1 March 2022 13:30 – 15:30 CET

#### **Global Evidence Review on Health and Migration: Strengthening information about health services related to NCDs for refugees and migrants to support evidence-based policy making on migration and health**

1 March 2022 14:00 – 15:00 CET

#### **Malaria vaccine R&D and immunization: lessons learned and considerations for global health impact**

3 March 2022 09:00 – 12:00 ET

#### **Immunization and vaccines related implementation research advisory committee (IVIR-AC) - March 2022**

7 – 11 March 2022

::::::

### **New WHO Publications**

<https://www.who.int/publications/>

*Selected Titles*

25 February 2022

#### **Shaping the global innovation and access landscape for better paediatric medicines**

### *Overview*

The lack of appropriate paediatric medicines and formulations is hindering the achievement of the Sustainable Development Goals and universal health coverage and is putting children's lives at risk. The Global Accelerator for Paediatric Formulations Strategy (GAP-f) 2022–2024 strategy builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. With this new strategy, we are excited to increase our footprint into a broader set of diseases to bring us closer to our vision of all children having equitable access to the medicines they need.

23 February 2022

### [Annexes to the recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19](#)

23 February 2022

### [Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19](#)

22 February 2022

### [WHO Pharmaceuticals Newsletter - N°1, 2022](#)

21 February 2022

### [Global vaccine safety blueprint 2.0 \(GVS2.0\) 2021-2023](#)

### *Overview*

The lack of appropriate paediatric medicines and formulations is hindering the achievement of the Sustainable Development Goals and universal health coverage and is putting children's lives at risk. The Global Accelerator for Paediatric Formulations Strategy (GAP-f) 2022–2024 strategy builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. With this new strategy, we are excited to increase our footprint into a broader set of diseases to bring us closer to our vision of all children having equitable access to the medicines they need.

:::::  
:::::  
:::::

### **[CDC/ACIP \[U.S.\]](#) [to 26 Feb 2022]**

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases, Announcements [Selected]*

*No new digest content identified.*

:::::

### **[ACIP Meetings](#)**

*Next meeting scheduled for February 23-24, 2022*

[Draft Agenda – February 23-24, 2022](#)

[Presentations](#)

:::::

### **[MMWR Weekly: Current Volume \(71\)](#)**

February 25, 2022 / No. 8 [PDF of this issue](#)

- [Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022](#)
- [Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations — United States, 2021](#)
- [Antigen Test Positivity After COVID-19 Isolation — Yukon-Kuskokwim Delta Region, Alaska, January–February 2022](#)
- [Results from a Test-to-Release from Isolation Strategy Among Fully Vaccinated National Football League Players and Staff Members with COVID-19 — United States, December 14–19, 2021](#)
- [Pediatric Emergency Department Visits Before and During the COVID-19 Pandemic— United States, January 2019–January 2022](#)
- [Pediatric Emergency Department Visits Associated with Mental Health Conditions Before and During the COVID-19 Pandemic — United States, January 2019–January 2022](#)
- [Erratum: Vol. 71, No. 3](#)

:::::

### **Coronavirus Disease 2019 (COVID-19)- CDC**

*Approximately 25 announcements/reports/data summaries.*

- [2/25/22Transcript for CDC Media Telebriefing: Update on COVID-19](#)
- [2/25/22Cases in the U.S.](#)
- [2/25/22EARLY RELEASE: SARS-CoV-2 B.1.1.529 \(Omicron\) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022](#)
- [2/25/22CDC Media Telebriefing: Update on COVID-19](#)
- [2/25/22Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 25 Feb 2022 06:00:00 EST](#)

:::::

:::::

**Africa CDC** [to 26 Feb 2022]

<http://www.africacdc.org/>

*News*

### **Tropical Storm Ana Hits hard five countries in the Southern Africa Region**

28 January 2022

*Africa CDC News*

### **Capacity building for South Sudan health emergency responders on the Incident Management System**

26 January 2022

*Press Releases*

### **Parsyl partners with Africa CDC to distribute 10,000 vaccine monitoring devices in support of continent's COVID-19 response**

:::::

:::::

**China CDC** <http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 26 Feb 2022]

<http://en.nhc.gov.cn/>

*News*

**[Feb 26: Daily briefing on novel coronavirus cases in China](#)**

On Feb 25, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 249 new cases of confirmed infections.

**[China widens choices for COVID-19 booster shots](#)**

Updated: 2022-02-21 | CHINA DAILY

**[Second medical team from mainland arrives in Hong Kong in fighting latest COVID-19 outbreak](#)**

2022-02-21

**National Medical Products Administration – PRC** [to 26 Feb 2022]

<http://english.nmpa.gov.cn/>

*News*

**[Over 3.1 billion COVID-19 vaccine doses administered on Chinese mainland](#)**

2022-02-25

The number of COVID-19 vaccine doses administered on the Chinese mainland had reached over 3.1 billion by Wednesday, data from the National Health Commission showed.

**[CCDC Weekly Reports: Current Volume \(4\)](#)**

2022-02-25 / No. 8 PARASITIC DISEASE ISSUE

[View PDF of this issue](#)

- [Preplanned Studies: A Knowledge Survey on Health Education of Echinococcosis Among Students — Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China, 2020](#)
- [Preplanned Studies: Intestinal Protozoan Infections in Patients with Diarrhea — Shanghai Municipality, Zhenjiang City, and Danyang City, China, 2011–2015 and 2019–2021](#)
- [Preplanned Studies: Transmission Risks of Mountain-Type Zoonotic Visceral Leishmaniasis — Six Endemic Provincial-Level Administrative Divisions, China, 2015–2020](#)
- [Commentary: Ending the “Neglect” to End Neglected Tropical Diseases](#)

:::::  
:::::  
:::::

**Contents [click to move among sections]**

::

***Contents [click to move among sections]***

:: *Coronavirus [COVID-19] - WHO*

:: *Emergencies*

:: *Organization Announcements*

:: *Journal Watch*

## ***Milestones - Perspectives***

- :: Coronavirus [COVID-19] - WHO
- :: Emergencies
- :: Organization Announcements
- :: Journal Watch

:::::::  
:::::::  
:::::::

## ***Organization Announcements***

### *Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

### **Airfinity** [to 26 Feb 2022]

<https://www.airfinity.com/insights>

*INSIGHTS & COMPANY NEWS*

*No new digest content identified.*

### **Paul G. Allen Frontiers Group** [to 26 Feb 2022]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

### **BMGF - Gates Foundation** [to 26 Feb 2022]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*No new digest content identified.*

### **Bill & Melinda Gates Medical Research Institute** [to 26 Feb 2022]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 26 Feb 2022]  
<https://carb-x.org/>  
*News*  
*No new digest content identified.*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 26 Feb 2022]  
<https://centerforvaccineethicsandpolicy.net/>  
*News/Analysis/Statements*  
:: [\*\*Informed Consent: A Monthly Review – February 2022\*\*](#) is now posted [here](#)  
:: Past weekly editions and posting of all segments of **Vaccines and Global Health: The Week in Review** are [available here](#).  
:: [\*\*Statement on ICF \[Informed Consent Form\] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse\*\*](#)

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 26 Feb 2022]  
<http://cepi.net/>  
*Latest News*  
[\*\*Japan pledges US\\$300 million to CEPI's pandemic preparedness plan\*\*](#)  
This investment comes at a critical time as the global community strives to end the acute phase of the COVID-19 pandemic and ensure that the world is better prepared to respond to future viral threats.  
End Pandemics  
25 Feb 2022

[\*\*UK pledges £160 million to CEPI to boost global vaccine development\*\*](#)  
Funding will support CEPI's work to cut new vaccine development time to 100 days, which could save millions of lives around the world.  
End Pandemics  
24 Feb 2022

[\*\*New global vaccine trial launched to evaluate fractional COVID-19 booster shots\*\*](#)  
CEPI will provide up to US \$8.7 million (AU \$12.3million) to support the trial, led by the Murdoch Children's Research Institute (MCRI), Australia, with support from PATH.  
COVAX  
21 Feb 2022

[\*\*CEPI, THSTI and Panacea Biotech partner to develop broadly protective Betacoronavirus vaccines\*\*](#)  
CEPI will provide funding of up to \$12.5m to Indian consortium, the sixth award under its programme to develop broadly protective coronavirus vaccines  
21 Feb 2022

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 26 Feb 2022]  
<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 26 Feb 2022]

<https://dukeghic.org/>

*Our Blog*

*No new digest content identified.*

**EDCTP** [to 26 Feb 2022]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

25 February 2022

**SFC HIV-Crypto consortium starts trial on improved treatment of cryptococcal meningitis in advanced HIV disease**

**Emory Vaccine Center** [to 26 Feb 2022]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 26 Feb 2022]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 26 Feb 2022]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*New Resources*

**Promotional communications for influenza vaccination programmes Added February 25, 2022**

**Public health interventions and infectious diseases amongst children in low- and middle-income countries: overview of reviews Added February 23, 2022**

**Water, sanitation and hygiene (WASH) and undernutrition and governance in children under five in sub-Saharan Africa Added February 21, 2022**

**Strategies intended to address vaccine hesitancy: overview of reviews (search up to November 2014) Added February 20, 2022**

**Fondation Mérieux** [to 26 Feb 2022]

<http://www.fondation-merieux.org/>

*News, Events*

*Announcement*

**Passing of Professor François Gros**

February 20, 2022 - Lyon, France

The Mérieux Foundation was deeply moved to learn of the death of Professor François Gros, President of Honor of its Board of Directors, on February 18, 2022.

A French biologist, he was internationally recognized for his contribution to the discovery of messenger RNA and for his career as a researcher and teacher dedicated to the study of genes and their role in the regulation of cellular functions.

Head of the Pasteur Institute from 1976 to 1982, advisor to Prime Ministers Pierre Mauroy and Laurent Fabius, he was also Permanent Secretary of the French Academy of Sciences and member of the Institut de France...

**Gavi** [to 26 Feb 2022]

<https://www.gavi.org/>

*News Releases*

*No new digest content identified.*

**GHIT Fund** [to 26 Feb 2022]

<https://www.ghitfund.org/newsroom/press>

*No new digest content identified.*

**Global Fund** [to 26 Feb 2022]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

23 February 2022

**Five African Presidents Launch Global Fund's US\$18 Billion Campaign to Restore Progress Against AIDS, TB and Malaria Amid COVID-19 Disruption**

- Presidents of DRC, Kenya, Rwanda, Senegal and South Africa join global leaders, communities, civil society organizations and private sector partners to kick off the Global Fund's Seventh Replenishment campaign.
- US\$18 billion would save 20 million lives, cut HIV, TB and malaria deaths by 65% and strengthen health systems to reinforce pandemic preparedness.

**Global Fund Applauds UK Contribution to the COVID-19 Response Mechanism**

25 February 2022

GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria applauds the decision by the United Kingdom Foreign, Commonwealth & Development Office to contribute GBP 60 million to the Global Fund's COVID-19 Response Mechanism...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 26 Feb 2022]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 26 Feb 2022]

<http://www.hilleman-labs.org/>

*News & Insights*

22 February 2022

**[Hilleman Laboratories breaks ground on pilot cGMP facility for vaccine development](#)**

*New facility is part of SGD80 million vaccine development and manufacturing hub in Singapore*

**HHMI - Howard Hughes Medical Institute** [to 26 Feb 2022]

<https://www.hhmi.org/news>

*Press Room*

Research Feb 23 2022

**[How Some Gut Microbes Awaken Zombie Viruses in Their Neighbors](#)**

Gut bacteria brew all sorts of chemicals, but we don't know what most of them do. A new study suggests that one such compound, previously linked to cancer, may serve as a bizarre weapon in microbial skirmishes.

**Human Vaccines Project** [to 26 Feb 2022]

<http://www.humanvaccinesproject.org/>

*News*

*HVP COVID Report*

Feb 18, 2022

**[Kristen Jill Abboud: How Many Doses of COVID-19 Vaccines Are Enough?](#)**

**IAVI** [to 26 Feb 2022]

<https://www.iavi.org/>

*Latest News*

*No new digest content identified*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 26 Feb 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

23/02/2022

**[Afghanistan: Global support critical as COVID runs r...](#)**

21/02/2022

**[Madagascar: Red Cross teams rush to avert a tragedy](#)**

**Institut Pasteur** [to 26 Feb 2022]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press release*

21.02.2022

**[Transplantation chemotherapy eliminates regenerative capacity of brain's innate immune cells](#)**

Annually over 50,000 bone marrow transplants occur worldwide as a therapy for multiple cancerous and non-cancerous...

*Press release*

21.02.2022

**[Death of Professor François Gros, on February 18, 2022](#)**

**IOM / International Organization for Migration** [to 26 Feb 2022]

<http://www.iom.int/press-room/press-releases>

*News - Selected*

*News*

24 Feb 2022

**[Statement on the Situation in Ukraine: IOM Director General António Vitorino](#)**

**ISC / International Science Council** [to 26 Feb 2022]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*News Blogs Podcasts*

**[Call for expressions of interest to evaluate the "Leading Integrated Research for Agenda 2030 in Africa" funding programme](#)**

24.02.2022

## **Heide Hackmann to step down as CEO of International Science Council**

21.02.2022

The International Science Council (ISC) today announces that Heide Hackmann will step down as Chief Executive Officer. Mathieu Denis, Science Director, will become Acting CEO, and a recruitment process for a new CEO of the ISC is underway.

Heide Hackmann has served as Chief Executive Officer of the International Science Council (ISC) since its creation in 2018, and as Executive Director of the ISC's two predecessor organizations: the International Social Science Council (ISSC), from 2006 to 2015, and the International Council for Science (ICSU), from 2015 to 2018...

### **IVAC** [to 26 Feb 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

### **IVI** [to 26 Feb 2022]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

### **Johns Hopkins Center for Health Security** [to 26 Feb 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

#### **Health Security Releases Special Feature on US Gene Drive Governance**

February 24, 2022

### **MSF/Médecins Sans Frontières** [to 26 Feb 2022]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*War and conflict*

#### **MSF assesses response as Ukraine conflict escalates**

Statement 25 Feb 2022

*Nigeria*

#### **Tackling deadly and difficult-to-diagnose Lassa fever**

Project Update 25 Feb 2022

*Niger*

#### **Airstrike kills 12 people including children in south Niger**

Press Release 21 Feb 2022

### **National Academy of Sciences - USA** [to 26 Feb 2022]

<http://www.nasonline.org/news-and-multimedia/>

*News*

*No new digest content identified.*

**National Vaccine Program Office - U.S. HHS** [to 26 Feb 2022]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 26 Feb 2022]

<http://www.nih.gov/news-events/news-releases>

*News Releases*

**[People from racial, ethnic, and other groups report frequent COVID-19-related discrimination](#)**

February 24, 2022 — Study highlights the need for public health messaging strategies that address biases against all population groups that have been marginalized.

**OECD** [to 26 Feb 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

*Newsroom*

**[Statement from OECD Secretary-General on initial measures taken in response to Russia's large scale aggression against Ukraine](#)**

Following on from yesterday's statement condemning the large scale aggression by Russia against Ukraine in the strongest possible terms and as part of its urgent reconsideration of all cooperation with Russia, the OECD Council has taken a number of initial decisions today.

25 Feb 2022

**[Plastic pollution is growing relentlessly as waste management and recycling fall short, says OECD](#)**

The world is producing twice as much plastic waste as two decades ago, with the bulk of it ending up in landfill, incinerated or leaking into the environment, and only 9% successfully recycled, according to a new OECD report.

22 Feb 2022

**OXFAM** [to 26 Feb 2022]

<https://www.oxfam.org/en/>

*Press Releases*

**[EU countries fall short of their promises to stop tax havens](#)**

24 February 2022

Today, European ministers updated the EU's list of tax havens. The update added no countries to the blacklist and 10 countries to the greylist.

**[New EU proposal on sustainable business needs fixing to work for people and the planet](#)**

23 February 2022

Today, the European Commission put forward a proposal for a law to clean up supply chains worldwide and make business sustainable. This new law will introduce important reforms only applying to a small group of very large companies selling goods and services on the EU market. Contrary to the Commission's initial ambitions, it does not include significant reforms to directors' duties.

**PATH** [to 26 Feb 2022]  
<https://www.path.org/media-center/>  
*Press Releases*  
*No new digest content identified.*

**Sabin Vaccine Institute** [to 26 Feb 2022]  
<http://www.sabin.org/updates/pressreleases>  
*Statements and Press Releases*  
*No new digest content identified.*

**UNAIDS** [to 26 Feb 2022]  
<http://www.unaids.org/en>  
*Selected Press Releases/Reports/Statements*  
23 February 2022  
**"They [the transgender community] don't have to be products. They can be producers too"**  
22 February 2022  
**What's the impact of the new HIV variant on the HIV response?**

21 February 2022  
**Four years of the Fast-Track cities project—what have we achieved and learned, and what is next?**

21 February 2022  
**Many key populations avoid health services**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 26 Feb 2022]  
<http://www.unhcr.org/en-us/media-centre.html>  
*Selected News Releases, Announcements*  
*No new digest content identified.*

**UNICEF** [to 26 Feb 2022]  
<https://www.unicef.org/media/press-releases>  
*Press Releases, News Notes, Statements [Selected]*  
*No new digest content identified.*

**Unitaid** [to 26 Feb 2022]

<https://unitaid.org/>

*Featured News*

23 February 2022

**The ACT-A Oxygen Emergency Taskforce...one year on**

21 February 2022

**In memory of Dr Paul Farmer**

...As co-founder and chief strategist of PIH, his influence was integral to the delivery of several successful joint projects with Unitaid, including one of Unitaid's flagship TB investments, which aimed at improving treatment for multidrug-resistant TB around the world...

21 February 2022

**Unitaid appoints Tenu Avafia Deputy Executive Director**

Geneva – Unitaid is pleased to welcome Tenu Avafia as its Deputy Executive Director. Tenu brings over 20 years of professional and managerial experience in public health, human rights inclusive development and trade-related matters across country, regional and global settings...

**Vaccine Equity Cooperative [nee Initiative]** [to 26 Feb 2022]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 26 Feb 2022]

<https://www.vaccineacceptance.org/>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 26 Feb 2022]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 26 Feb 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**Vaccine Update for Providers**

*February 2022*

*Announcements: Register for the March webinar; find out about new and updated videos*

On March 16, 2022, at noon ET, Dr. Offit will discuss: "Approving COVID-19 Vaccines for Children: When Do We Know Enough?"

[Registration](#) open!

**Wellcome Trust** [to 26 Feb 2022]

<https://wellcome.ac.uk/news>

*News, Opinion, Reports*

*Opinion*

Author: Raphael Sonabend

**[Standardising health and climate metrics to drive urgent action](#)**

22 February 2022

**The Wistar Institute** [to 26 Feb 2022]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 26 Feb 2022]

<https://www.wfpha.org/>

*Latest News - Blog*

*No new digest content identified.*

**World Bank** [to 26 Feb 2022]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

**[Government of Nepal and World Bank Sign Agreement of \\$18 Million for Nepal's COVID-19 health response including vaccines](#)**

KATHMANDU, February 25, 2022 – The Government of Nepal and the World Bank today signed an agreement for a second additional concessional loan financing of \$18 million (Rs. 2.14 billion) for COVID-19...

Date: February 25, 2022 Type: Press Release

**[COVID-19 Trade Policy Database: Food and Medical Products](#)**

Many governments are using trade policy measures to increase the availability of medical and food products during the COVID-19 pandemic. Tracking them is important for assessing their incidence, effectiveness...

Date: February 25, 2022 Type: Brief

**World Customs Organization – WCO** [to 26 Feb 2022]

<http://www.wcoomd.org/>

*Latest News – Selected Items*

21 February 2022

**[WCO Secretary General addresses data, e-commerce and illicit trade at the Munich Security Conference](#)**

...The WCO-coordinated enforcement operations demonstrated that e-commerce has become one of the major conduits for illicit trade. Therefore, it has become essential to obtain access to good quality data for risk management purposes, using digital technology in a paperless trade environment. Like in the case of traditional containerized trade, where there is an established data flow from the trade

community to Customs, there is also a need for Customs to enhance cooperation with the e-commerce operators, including e-commerce platforms...

**World Organisation for Animal Health (OIE)** [to 26 Feb 2022]

<https://www.oie.int/en/media/news/>

*Press Releases, Statements*

*No new digest content identified.*

**WTO - World Trade Organisation** [to 26 Feb 2022]

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events*

**[WTO members agree on mid-June dates for reconvening MC12](#)**

23 February 2022

WTO members agreed on 23 February that the postponed 12th Ministerial Conference (MC12) will now take place during the week of 13 June in Geneva. The decision at a meeting of the organization's General Council was taken following the easing of COVID-19 pandemic restrictions in the host country Switzerland.

MC12 was due to take place from 30 November to 3 December 2021 but was postponed due to the outbreak of the Omicron variant of COVID-19, which led to the imposition of travel restrictions and quarantine requirements in Switzerland and many other European countries.

Ambassador Dacio Castillo of Honduras, the chair of the General Council, noted that fixing the dates for the eagerly awaited meeting should provide impetus to the WTO's work and focus for the discussion on ministerial outcomes. The exact dates of the meeting will be defined later, he noted.

"Let us work together, with the primary objective in mind, that the Conference will provide the WTO, and us here in Geneva, with an opportunity to demonstrate that the WTO can deliver," Ambassador Castillo declared. "Let us make this count."

The pandemic has twice forced the postponement of MC12. The meeting was originally scheduled to take place in June 2020 in Nur-Sultan, Kazakhstan.

::::::

***Editor's Note:***

This WTA announcement does not happen to note that resolution of TRIPS intellectual property issues around COVID vaccines has been confounded by recurring MC12 scheduling delays, as well as WTA decisions taken such resolution could not be achieved from meaningful work outside of the MC12 meeting format.

::::::

**ARM [Alliance for Regenerative Medicine]** [to 26 Feb 2022]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 26 Feb 2022]

<https://www.bio.org/press-releases>

*Press Releases, Letters, Testimony, Comments [Selected]*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 26 Feb 2022]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 26 Feb 2022]

<https://internationalbiotech.org/news/>

*News*

*Website still in "maintenance mode"*

**IFPMA** [to 26 Feb 2022]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

**Three priorities to urgently increase access to COVID-19 vaccines**

25 February 2022

*[See COVID above for detail]*

**Position paper - In-country testing of Advanced Therapy Medicinal Products**

25 February 2022

This paper discusses specifics of ATMPs, where traditional in-country testing is challenging, outlining existing control strategies to detect potential issues, with recommendations to waive in-country testing without compromising product safety, quality and efficacy and in compliance with requirements, i.e., by recognition of certificates from countries with mature National Regulatory Authorities (NRAs).\*

\* Mature NRAs refers to Stringent Regulatory Authorities, SRAs [1-3]. A list of SRAs has been published by the WHO here. Once the WHO listed authority (WLA) system is fully implemented the term WLA will replace the term SRA.

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**International Alliance of Patients' Organizations – IAPO** [to 26 Feb 2022]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

**Invitation to participate in our Global Health Technology Assessment Survey**

Tuesday, 22 February 2022

Patient involvement in Global Health Technology Assessment (HTA) is still in its infancy, although several efforts continue to be initiated in recent years.

In response, IAPO and DUKE NUS are conducting a global survey to assess patients' awareness, involvement and learning needs in HTA in order to develop training materials that meet the learning needs of patient organizations to support them to be meaningfully involved in HTA processes....

Take the survey in: [English](#) [Spanish](#) [Chinese](#) or [Thai](#)

**PhRMA** [to 26 Feb 2022]

<http://www.phrma.org/>

*Latest News [Selected]*

*No new digest content identified.*

\* \* \* \*

## **Contents [click to move among sections]**

*Contents [click to move **among sections**]*

- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

## **Milestones - Perspectives**

- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

\* \* \* \*

## **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 13, 2022 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>  
[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 24, Number 2: E107-163 Feb 2022

<https://journalofethics.ama-assn.org/issue/tactical-health-and-law-enforcement>

### **Tactical Health and Law Enforcement**

Tactical health involves providing field-based clinical support to law enforcement operations during frontline crisis interventions and prehospital emergency care. Health professional skill can inform individual officers' occupational health maintenance and help agents of the state navigate primary and secondary trauma and posttrauma experiences in field- and clinic-based settings. Tactical health expertise can also inform department- and agency-level policies, decisions, and responses to community health and safety threats. Ethical questions considered in this issue focus on the nature and scope of health professionals' collaborations with law enforcement personnel during and following critical event preparation and responses.

### **American Journal of Infection Control**

February 2022 Volume 50 Issue 2 p123-242

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

February 2022 Volume 62 Issue 2 p149-306

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

February 2022 112(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 106 (2022): Issue 2 (Feb 2022)

<https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

February 2022 Volume 175, Issue 2

<http://annals.org/aim/issue>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 303 February 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 26 Feb 2022)

[No new digest content identified]

**BMJ Global Health**

February 2022 - Volume 7 - 2

<https://gh.bmj.com/content/7/1>

[Reviewed earlier]

**BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 26 Feb 2022)

[No new digest content identified]

**BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 26 Feb 2022)

**[Pneumococcal meningitis and COVID-19: dangerous coexistence. A case report](#)**

*SARS-CoV-2 is the major cause of infections in humans since December 2019 and is top of the global health concern currently. Streptococcus pneumoniae is one of the leading pathogens of invasive bacterial diseases...*

Authors: Katarzyna Guziejko, Piotr Czupryna, Ewa Katarzyna Zielenkiewicz-Madejska and Anna Moniuszko-Malinowska

Citation: BMC Infectious Diseases 2022 22:182

Content type: Case report

Published on: 23 February 2022

**[Pneumococcal meningitis and COVID-19: dangerous coexistence. A case report](#)**

*SARS-CoV-2 is the major cause of infections in humans since December 2019 and is top of the global health concern currently. Streptococcus pneumoniae is one of the leading pathogens of invasive bacterial diseases...*

Authors: Katarzyna Guziejko, Piotr Czupryna, Ewa Katarzyna Zielenkiewicz-Madejska and Anna Moniuszko-Malinowska

Citation: BMC Infectious Diseases 2022 22:182

Content type: Case report

Published on: 23 February 2022

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 26 Feb 2022)

### **Development and validation of an instrument to measure pediatric nurses' adherence to ethical codes**

Authors: Raziye Beykmirza, Lida Nikfarid, Reza Negarandeh, Naeimeh Sarkhani and Mahboube Moradi Cherati

Content type: Research

25 February 2022

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 26 Feb 2022)

### **Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)**

*Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking.*

Authors: Mohammad Talaei, Sian Faustini, Hayley Holt, David A. Jolliffe, Giulia Vivaldi, Matthew Greenig, Natalia Perdek, Sheena Maltby, Carola M. Bigogno, Jane Symons, Gwyneth A. Davies, Ronan A. Lyons, Christopher J. Griffiths, Frank Kee, Aziz Sheikh, Alex G. Richter...

Citation: BMC Medicine 2022 20:87

Content type: Research article

Published on: 22 February 2022

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 26 Feb 2022)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 26 Feb 2022)

### **Association between risk perception and influenza vaccine hesitancy for children among reproductive women in China during the COVID-19 pandemic: a national online survey**

*In China, the national prevalence of parental influenza vaccine hesitancy (IVH) during the pandemic of coronavirus disease 2019 (COVID-19), and the association between risk perception and parental IVH are stil...*

Authors: Min Du, Liyuan Tao and Jue Liu

Citation: BMC Public Health 2022 22:385

Content type: Research

Published on: 23 February 2022

### **Association between social media use and the acceptance of COVID-19 vaccination among the general population in Saudi Arabia – a cross-sectional study**

*The Coronavirus Disease of 2019 (COVID-19) pandemic is a worldwide global public health threat. Although acceptance of COVID-19 vaccination will be a critical step in combating the pandemic, achieving high uptake...*

Authors: Sahar S. Othman, Abeer Alsuwaidi, Rafal Aseel, Reema Alotaibi, Reem Bablgoom, Ghadeer alsulami, Razan Alharbi and Ranya Ghamri

Citation: BMC Public Health 2022 22:375

Content type: Research

Published on: 21 February 2022

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 26 Feb 2022)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

February 2022 - Volume 27 - 1

<https://ebm.bmj.com/content/27/1>

[Reviewed earlier]

### **BMJ Open**

February 2022 - Volume 12 - 2

<https://bmjopen.bmj.com/content/12/2>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 100(2); 2022 Feb 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/399608/>

[Reviewed earlier]

### **Cell**

Feb 17, 2022 Volume 185 Issue 4 p579-746

<https://www.cell.com/cell/current>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 48, Issue 2, Pages: 177-357 March 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 111, Issue 2 Pages: 333-518 February 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>  
[Reviewed earlier]

**Clinical Therapeutics**  
December 2021 Volume 43 Issue 12 p2041-2172  
<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

**Clinical Trials**  
Volume 19 Issue 1, February 2022  
<https://journals.sagepub.com/toc/ctja/19/1>  
[Reviewed earlier]

**Conflict and Health**  
<http://www.conflictandhealth.com/>  
[Accessed 26 Feb 2022]  
[No new digest content identified]

**Contemporary Clinical Trials**  
Volume 113 February 2022  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/113/suppl/C>  
[Reviewed earlier]

**The CRISPR Journal**  
Volume 5, Issue 1 / February 2022  
<https://www.liebertpub.com/toc/crispr/5/1>  
*Editorial*

**CRISPR Rewrites the Future of Medicine**  
Rodolphe Barrangou  
Published Online: 22 February 2022  
...As always, the CRISPR collaborative network relies on teamwork, encompassing leaders in academia, clinical settings, and regulatory agencies enabling industry pioneers to develop CRISPR drugs. Critical translational endeavors by genome-editing companies and their pharmaceutical partners are translating progress into actual therapies that patients need, barely 2 years after the initial dosing of SCD patient Victoria Gray.

Several ongoing studies are anticipated to corroborate the safety and efficacy of CRISPR medicines, with about 50 studies currently registered on [clinicaltrials.gov](https://clinicaltrials.gov). Active studies in the aforementioned disorders and immunotherapies will be joined by trials on lymphoma (CB010A), myeloma (CTX-120), leukemia (NTLA-5001), carcinoma (CTX-130), Leber congenital amaurosis (EDIT-101), angioedema (NTLA-2002) and others, with more than two dozen studies actively recruiting. Most activity is centered in the United States and China, with trials also taking place in the United Kingdom, Canada, France, Sweden, and New Zealand, illustrating the global enthusiasm for CRISPR-based therapies.

CRISPR's path to the clinic is reaching a critical point where clinical-stage development requires translational efforts by biotech pioneers joining forces with pharmaceutical companies to scale up these programs. Publicly disclosed partnerships include Intellia Therapeutics with Regeneron and Novartis; Editas Medicine with Bristol Myers Squibb and AskBio; CRISPR Therapeutics with Vertex and Bayer; Beam Therapeutics with Pfizer; and Caribou Biosciences with Abbvie. This trend has inspired additional partnerships and investments in up-and-coming players such as Mammoth Biosciences and Metagenomi, as well as fueling next-generation CRISPR startups such as Prime Medicine, Graphite Bio, LifeEDIT, Scribe Therapeutics, Tessera Therapeutics, Tome Biosciences, and Tune Therapeutics.

We thank our special issue guest editors, Annarita Miccio (Institut Imagine, Paris) and Matthew Porteus (Stanford University), for helping to shepherd this issue to completion. The articles in this issue illustrate how quickly translational efforts are progressing, how far into the clinic we already are, and set the stage for the expanded and accelerated deployment of CRISPR therapeutic payloads. We look forward to following this path in future issues of *The CRISPR Journal*.

*Guest Editorial*

### **CRISPR's Path to the Clinic**

Annarita Miccio

Pages:2–3

Published Online:22 February 2022

### **Current Genetic Medicine Reports**

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

February 2022 - Volume 35 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 21, Issue 4 Pages: 149-238 December 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 31, Issue 8, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

## **Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

*Commentary*

### **The Importance of Developing Rigorous Social Science Methods for Community Engagement and Behavior Change During Outbreak Response**

Henry C. Ashworth, Sara Dada, Conor Buggy, Shelley Lees

Published online by Cambridge University Press: 09 July 2020, pp. 685-690

*Abstract*

Despite growing international attention, the anthropological and socio-behavioral elements of epidemics continue to be understudied and under resourced and lag behind the traditional outbreak response infrastructure. As seen in the current 2019 coronavirus disease (COVID-19) pandemic, the importance of socio-behavioral elements in understanding transmission and facilitating control of many outbreak-prone pathogens, this is problematic. Beyond the recent strengthening of global outbreak response capacities and global health security measures, a greater focus on the socio-behavioral components of outbreak response is required. We add to the current discussion by briefly highlighting the importance of socio-behavior in the Ebola virus disease (EVD) response, and describe vital areas of future development, including methods for community engagement and validated frameworks for behavioral modeling and change in outbreak settings.

## **Disasters**

Volume 46, Issue 1 Pages: 1-298 January 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

## **EMBO Reports**

Volume 23 Issue 2 3 February 2022

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

## **Emerging Infectious Diseases**

Volume 28, Number 2—February 2022

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

## **Epidemics**

Volume 37 December 2021

<https://www.sciencedirect.com/journal/epidemics/vol/37/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[New issue; No digest content identified]

## **Ethics & Human Research**

Volume 44, Issue 1 Pages: 1-39 January–February 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

## **Ethics & International Affairs**

Winter 2021 (35.4) | December 2021

<https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/>

*TABLE OF CONTENTS*

*FEATURE*

### **On the Ethics of Vaccine Nationalism: The Case for the Fair Priority for Residents Framework**

Ezekiel J. Emanuel, Allen Buchanan, Shuk Ying Chan, Cécile Fabre, Daniel Halliday, R. J. Leland, Florencia Luna, Matthew S. McCoy, Ole F. Norheim, G. Owen Schaefer, Kok-Chor Tan, Christopher Heath Wellman

#### *Abstract*

COVID-19 vaccines are likely to be scarce for years to come. Many countries, from India to the U.K., have demonstrated vaccine nationalism. What are the ethical limits to this vaccine nationalism? Neither extreme nationalism nor extreme cosmopolitanism is ethically justifiable. Instead, we propose the fair priority for residents (FPR) framework, in which governments can retain COVID-19 vaccine doses for their residents only to the extent that they are needed to maintain a noncrisis level of mortality while they are implementing reasonable public health interventions. Practically, a noncrisis level of mortality is that experienced during a bad influenza season, which society considers an acceptable background risk. Governments take action to limit mortality from influenza, but there is no emergency that includes severe lockdowns. This “flu-risk standard” is a nonarbitrary and generally accepted heuristic. Mortality above the flu-risk standard justifies greater governmental interventions, including retaining vaccines for a country’s own citizens over global need. The precise level of vaccination needed to meet the flu-risk standard will depend upon empirical factors related to the pandemic. This links the ethical principles to the scientific data emerging from the emergency. Thus, the FPR framework recognizes that governments should prioritize procuring vaccines for their country when doing so is necessary to reduce mortality to noncrisis flu-like levels. But after that, a government is obligated to do its part to share vaccines to reduce risks of mortality for people in other countries. We consider and reject objections to the FPR framework based on a country: (1) having developed a vaccine, (2) raising taxes to pay for vaccine research and purchase, (3) wanting to eliminate economic and social burdens, and (4) being ineffective in combating COVID-19 through public health interventions.

## **Ethics, Medicine and Public Health**

Volume 20 February 2022

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/20/suppl/C>

[Reviewed earlier]

**The European Journal of Public Health**  
Volume 32, Issue 1, February 2022  
<https://academic.oup.com/eurpub/issue/32/1>  
[New issue; No digest content identified]

**Expert Review of Vaccines**  
Vol 21 (1) 2022  
<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

**Forum for Development Studies**  
Volume 48, 2021 - Issue 3  
<http://www.tandfonline.com/toc/sfds20/current>  
[Reviewed earlier]

**Genome Medicine**  
<https://genomemedicine.biomedcentral.com/articles>  
[Accessed 26 Feb 2022]  
[No new digest content identified]

**Global Health Action**  
Volume 15, Issue 1 (2022)  
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>  
[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**  
Vol. 9, No. 4 December 31, 2021  
<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]

**Global Legal Monitor – Library of Congress/USA**  
<https://www.loc.gov/collections/global-legal-monitor/>  
[Accessed 26 Feb 2022]  
[No new digest content identified]

**Global Public Health**  
Volume 17, Issue 3 (2022)  
<http://www.tandfonline.com/toc/rgph20/current>

*Article*

**Health equity and health system strengthening – Time for a WHO re-think**

N. Jensen, A. H. Kelly & M. Avendano

Pages: 377-390

Published online: 10 Jan 2021

***ABSTRACT***

The pursuit of health equity is foundational to the global health enterprise. But while moral concerns over health inequities can galvanise political commitment, how such concerns can or should translate into practice remains less clear. This paper reviews evolving ways that equity goals have featured in key World Health Organization (WHO)-related policy documents, before discussing the heuristic value and empirical traction that the concept of equity can bring to the health system strengthening (HSS) agenda. We argue that while health equity is often presented as the overarching goal of HSS, in practice this is typically circumscribed to the provision of healthcare services. Although healthcare equity is important, we suggest that this narrow focus risks losing sight of the structural political, social and economic drivers of health and health inequities, as well as the broader contexts of care and complex socio-political mechanisms through which health systems are strengthened. Drawing on new lines of empirical inquiry, we propose that broadening the equity lens for HSS offers exciting opportunities to put health systems at the heart of a more ambitious equity agenda in global health.

**Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 26 Feb 2022]

**How are global health policies transferred to sub-Saharan Africa countries? A systematic critical review of literature**

*Most sub-Saharan Africa countries adopt global health policies. However, mechanisms with which policy transfers occur have largely been studied amongst developed countries and much less in low- and middle-income countries...*

Authors: Walter Denis Odoch, Flavia Senkubuge, Ann Bosibori Masese and Charles Hongoro

Citation: Globalization and Health 2022 18:25

Content type: Research

Published on: 23 February 2022

**Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together**

*With large swathes of the world's population—majority clustered in low- and middle-income countries—still yet to receive the minimum of two doses of the COVID-19 vaccine; The need to address the failures of in...*

Authors: Sudhan Rackimuthu, Kapil Narain, Arush Lal, Faisal A. Nawaz, Parvathy Mohanan, Mohammad Yasir Essar and Henry Charles Ashworth

Citation: Globalization and Health 2022 18:23

Content type: Commentary

Published on: 22 February 2022

**Health and Human Rights**

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 17 - Special Issue 1 - January 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

#### ***SPECIAL ISSUE: Country Responses to the COVID-19 Pandemic***

*Articles analyzing country responses in Australia, New Zealand, Canada, U.S., Belgium, Netherlands, Sweden, France, Italy*

### **Health Policy and Planning**

Volume 37, Issue 2, February 2022

<https://academic.oup.com/heapol/issue/37/2>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 26 Feb 2022]

[No new digest content identified]

### **Human Gene Therapy**

Volume 33, Issue 3-4 / February 2022

<https://www.liebertpub.com/toc/hum/33/3-4>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Online Article*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 11, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

### **Immunity**

Feb 08, 2022 Volume 55 Issue 2 p185-376

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>  
[Accessed 26 Feb 2022]  
[No new digest content identified]

**Infectious Diseases of Poverty**  
<http://www.idpjurnal.com/content>  
[Accessed 26 Feb 2022]  
[No new digest content identified]

**International Health**  
Volume 14, Issue 1, January 2022  
<https://academic.oup.com/inthealth/issue/14/1>  
[Reviewed earlier]

**International Human Rights Law Review**  
Volume 10 (2021): Issue 2 (Dec 2021)  
<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>  
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**  
Vol 9, No 1 (2022) January 2022  
<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>  
[Reviewed earlier]

**International Journal of Epidemiology**  
Volume 51, Issue 1, February 2022  
<https://academic.oup.com/ije/issue>  
[New issue; No digest content identified]

**International Journal of Human Rights in Healthcare**  
Volume 14 Issue 5 2021  
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>  
*Table of Contents*  
[Reviewed earlier]

**JAMA**  
February 22, 2022, Vol 327, No. 8, Pages 703-790  
<https://jamanetwork.com/journals/jama/currentissue>  
*Original Investigation*  
[\*\*Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications\*\*](#)

Torri D. Metz, MD, MS; Rebecca G. Clifton, PhD; Brenna L. Hughes, MD, MS; et al.  
free access has active quiz has multimedia has audio  
JAMA. 2022;327(8):748-759. doi:10.1001/jama.2022.1190

This cohort study evaluates the association of SARS-CoV-2 infection with serious maternal morbidity or mortality related to hypertensive disorders of pregnancy, postpartum hemorrhage, or infection other than SARS-CoV-2.

*Viewpoint*

**The US Supreme Court's Rulings on Large Business and Health Care Worker Vaccine Mandates - Ramifications for the COVID-19 Response and the Future of Federal Public Health Protection**

Lawrence O. Gostin, JD; Wendy E. Parmet, JD; Sara Rosenbaum, JD  
JAMA. 2022;327(8):713-714. doi:10.1001/jama.2022.0852

This Viewpoint examines the recent US Supreme Court rulings on government mandates for COVID-19 vaccination and how these decisions might affect the ongoing pandemic response as well as the future of public health.

*JAMA Patient Page*

**COVID-19 and Pregnancy**

Kristin Walter, MD, MS  
free access has multimedia has audio  
JAMA. 2022;327(8):790. doi:10.1001/jama.2021.22679

This JAMA Patient Page describes characteristics of COVID-19 among pregnant people and vaccination recommendations for people who are pregnant or breastfeeding.

**JAMA Network**

**COVID-19 Update February 26, 2022**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

**JAMA Pediatrics**

February 2022, Vol 176, No. 2, Pages 115-212  
<https://jamanetwork.com/journals/jamapediatrics/currentissue>  
[Reviewed earlier]

**JBI Evidence Synthesis**

February 2022 - Volume 20 - Issue 2  
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>  
[New issue; No digest content identified]

**Journal of Adolescent Health**

February 2022 Volume 70 Issue 2 p171-350  
<https://www.jahonline.org/current>  
[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 47, issue 1, February 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-1>

[Reviewed earlier]

**Journal of Development Economics**

Volume 155 March 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/155/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

February 2022 - Volume 76 - 2

<https://jech.bmjjournals.org/content/76/2>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 14, Issue 4 Pages: 257-345 December 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 17, Issue 3, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 33, Number 1, February 2022

<https://muse.jhu.edu/issue/47329>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 24, issue 1, February 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-1>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 20, 2022 \_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 225, Issue 2, 15 January 2022

<https://academic.oup.com/jid/issue/225/2>

[New issue; No digest content identified]

**Journal of Medical Ethics**

February 2022 - Volume 48 - 2

<http://jme.bmjjournals.org/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 9, Issue 1 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

February 2022 Volume 241 p1-266

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 26 Feb 2022]

[No new digest content identified]

**Journal of Public Health Management & Practice**

January/February 2022 - Volume 28 - Issue 1

<https://jphmp.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 43, issue 1, March 2022

<https://link.springer.com/journal/41271/volumes-and-issues/43-1>

**COVID-19 lockdown implementation in Ghana: lessons learned and hurdles to overcome**

Authors - Abraham Assan, Hawawu Hussein, David N. K. Agyeman-Duah

Content type: Viewpoint

Open Access

Published: 04 January 2022

**A public health framework for the equitable global allocation of vaccines: COVID-NEEDS**

Authors - Vageesh Jain, Paula Lorgelly

Content type: Viewpoint

Published: 13 January 2022

**Vaccine distribution exacerbates the social divide**

Authors - Marta Lomazzi, Meru Sheel, Asha Singh

Content type: Federation Page

Published: 19 January 2022

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

February 2022 Volume 19 Issue 187

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 29, Issue 1, January 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 96 Number 4 February 2022

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

**The Lancet**

Feb 26, 2022 Volume 399 Number 10327 p769-884, e7-e10

<https://www.thelancet.com/journals/lancet/issue/current>

*Comment*

### **Waning effectiveness of COVID-19 vaccines**

Hiam Chemaitley, Laith J Abu-Raddad

In *The Lancet*, Peter Nordström and colleagues<sup>1</sup> report the effectiveness of several COVID-19 vaccines and different vaccine schedules against any documented SARS-CoV-2 infection and against severe COVID-19, for up to 9 months of follow-up. Data for 842 974 matched pairs of vaccinated and unvaccinated individuals in this retrospective cohort study were retrieved from the Swedish national registers. These registers track health outcomes for all registered individuals nationwide. Both cohorts had a median age of 52·7 years (IQR 37·0–67·5) and included mostly women (500 297 [59·3%] in each cohort) and individuals born in Sweden (703 666 [83·5%] in the vaccinated cohort vs 578 647 [68·6%] in the unvaccinated cohort). Follow-up started 14 days after the second dose for each person vaccinated with BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), ChAdOx1 nCoV-19 (Oxford–AstraZeneca), or mixed ChAdOx1 nCoV-19 and an mRNA vaccine and their unvaccinated matches. Effectiveness estimates were adjusted for date of second dose, age, sex, domestic support (proxy for disability), education, place of birth, and comorbidities. The study was completed on Oct 4, 2021, before the advent of the omicron (B.1.1.529) variant...

*Articles*

### **Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden**

Peter Nordström, Marcel Ballin, Anna Nordström

### **The Lancet Child & Adolescent Health**

Feb 2022 Volume 6 Number 2 p71-136, e5

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Feb 2022 Volume 4 Number 2 e75-e148

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Feb 2022 Volume 10 Number 2 e154-e297

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Feb 2022 Volume 22 Number 2 p151-296, e41-e65

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Feb 2022 Volume 7 Number 2 e93-e194

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Feb 2022 Volume 10 Number 2 p121-220, e11-e24

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 26, issue 2, February 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-2>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 42 Issue 2, February 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 99, Issue 4 Pages: 853-1206 December 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Nature**

Volume 602 Issue 7898, 24 February 2022

<https://www.nature.com/nature/volumes/602/issues/7898>

*Editorial* | 22 February 2022

**[Female scientists in Africa are changing the face of their continent](#)**

Why international researchers should be lining up to collaborate with women working in science across Africa.

*World View* | 22 February 2022

**[Commit to transparent COVID data until the WHO declares the pandemic is over](#)**

Governments and organizations responsible for crucial COVID data must do more not less.

Edouard Mathieu

*Comment* | 22 February 2022

**[COVID-19: talk of 'vaccine hesitancy' lets governments off the hook](#)**

Go beyond the attitudes of individuals and focus more on what governments must do to build people's trust and ensure easy access to vaccines for all.

Katie Attwell, Adam Hannah, Julie Leask

*Article* | 23 December 2021 | Open Access

### **Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization**

Plasma from individuals vaccinated with BNT162b2 exhibits 22-fold less neutralization capacity against Omicron (B.1.1.529) than against an ancestral SARS-CoV-2 strain but residual neutralization is maintained in those with high levels of neutralization of ancestral virus.

Sandile Cele, Laurelle Jackson, Alex Sigal

*Article* | 23 December 2021 | Open Access

### **Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies**

A high-throughput yeast display platform is used to analyse the profiles of mutations in the SARS-CoV-2 receptor-binding domain (RBD) that enable escape from antibodies, and suggests that most anti-RBD antibodies can be escaped by the Omicron variant.

Yunlong Cao, Jing Wang, Xiaoliang Sunney Xie

*Article* | 23 December 2021

### **Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift**

Pseudovirus assays and surface plasmon resonance show that the Omicron receptor-binding domain binds to human ACE2 with increased affinity relative to the ancestral virus, and that most neutralizing antibodies are considerably less potent against Omicron.

Elisabetta Cameroni, John E. Bowen, Davide Corti

*Article* | 23 December 2021

### **Considerable escape of SARS-CoV-2 Omicron to antibody neutralization**

An isolate of the Omicron variant of SARS-CoV-2 was completely or partially resistant to neutralization by all nine clinically approved monoclonal antibodies tested.

Delphine Planas, Nell Saunders, Olivier Schwartz

*Article* | 23 December 2021

### **Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2**

The B.1.1.529/Omicron variant of SARS-CoV-2 is resistant to neutralization by serum not only from patients who recovered from COVID-19, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines.

Lihong Liu, Sho Iketani, David D. Ho

*Article* | 31 December 2021

### **Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron**

Sera from unvaccinated, vaccinated, and previously infected and vaccinated individuals show reduced neutralizing and spike protein-binding activity towards the Omicron (B.1.1.529) variant of SARS-CoV-2 compared to other variants.

Juan Manuel Carreño, Hala Alshammary, Florian Krammer

## **Nature Biotechnology**

Volume 40 Issue 2, February 2022

<https://www.nature.com/nbt/volumes/40/issues/2>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 26 Feb 2022)

[No new digest content identified]

## **Nature Genetics**

Volume 54 Issue 2, February 2022

<https://www.nature.com/ng/volumes/54/issues/2>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 6 Issue 2, February 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/2>

### ***Focus on vaccine inequity***

Equitable distribution of resources to fight COVID-19 is a global challenge. In a collection of research and opinion articles, researchers, public health officials, intellectual property experts, leaders of international organizations, and activists explain how global inequities in COVID-19 vaccine allocation continue fuelling the pandemic, and discuss ways to address these disparities.

*Editorial* | 31 January 2022

### **In a pandemic, national and global interests converge**

In ten contributions, mathematical modellers, public health officials, intellectual property experts and activists explain how vaccine inequities continue to fuel the pandemic, and how multilateral cooperation can help.

*World View* | 31 January 2022

### **Vaccine inequity is unethical**

Ethical principles dictate that limited, life-saving resources should be allocated fairly. Keymanthri Moodley affirms that achieving global distributive justice is one of the greatest challenges of the COVID-19 pandemic, and current distribution strategies are ethically indefensible.

Keymanthri Moodley

*Research Briefing* | 24 February 2022

### **The emergence of COVID-19 vaccine resistance depends on human choices**

The probability of the emergence of SARS-CoV-2 vaccine-resistant variants depends on the number of daily infections permitted by society, and the rate and penetrance of vaccination. Rapidly vaccinating all eligible people while maintaining strict physical distancing measures can prevent the evolution of vaccine resistance.

*Article* | 31 January 2022 | Open Access

### **Equitable access to COVID-19 vaccines makes a life-saving difference to all countries**

Using data-driven mathematical modelling that combines viral evolution with epidemiological dynamics, Ye et al. show that COVID-19 vaccine inequity leads to the emergence of new variants and new waves

of the pandemic, while equitable allocation of vaccine doses reduces case counts and fatalities in all countries.

Yang Ye, Qingpeng Zhang, Daniel Dajun Zeng

## **Nature Medicine**

Volume 28 Issue 2, February 2022

<https://www.nature.com/nm/volumes/28/issues/2>

*Comment* | 12 January 2022

### **The French health pass holds lessons for mandatory COVID-19 vaccination**

The passe sanitaire increased levels of vaccination, but to a lower extent among the most vulnerable, and did not reduce vaccine hesitancy itself, showing the importance of outreach to underserved communities and the potential limits of mandatory vaccination policies.

Jeremy K. Ward, Fatima Gauna, Patrick Peretti-Watel

*Perspective* | 10 February 2022

### **A roadmap to increase diversity in genomic studies**

Based on their experience of setting up genomic studies in underrepresented populations, the authors propose a roadmap to enhancing inclusion and ensuring that the health benefits of genomics advances are accessible to all.

Segun Fatumo, Tinashe Chikowore, Karoline Kuchenbaecker

*Article* / 17 February 2022

### **Influenza virus infection history shapes antibody responses to influenza vaccination**

Recent prior influenza A infection is associated with elevated hemagglutinin-inhibiting antibody responses and greater breadth of reactivity to influenza strains following vaccination, suggesting that infection history boosts vaccine responses.

Maria Auladell, Hoang Vu Mai Phuong, Annette Fox

*Article* | 14 December 2021 | Open Access

### **Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection**

A self-controlled case series using individual-patient-level data from over 38 million people aged 16 years and over, reveals an increased risk of myocarditis within a week of receiving a first dose of ChAdOx1, BNT162b2 and mRNA-1273 vaccines, which was further increased after a second dose of either mRNA vaccine. SARS-CoV-2 infection was associated with even greater risk of myocarditis, as well as pericarditis and cardiac arrhythmia.

Martina Patone, Xue W. Mei, Julia Hippisley-Cox

## **Nature Reviews Genetics**

Volume 23 Issue 2, February 2022

<https://www.nature.com/nrg/volumes/23/issues/2>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 22 Issue 2, February 2022

<https://www.nature.com/nri/volumes/22/issues/2>  
[Reviewed earlier]

**Nature Reviews Drug Discovery**  
Volume 21 Issue 2, February 2022  
<https://www.nature.com/nrd/volumes/21/issues/2>  
[Reviewed earlier]

**New England Journal of Medicine**  
February 24, 2022 Vol. 386 No. 8  
<https://www.nejm.org/toc/nejm/medical-journal>  
*Original Articles*  
**[Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents](#)**  
S.M. Olson and Others

**[Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants](#)**  
D.W. Eyre and Others

*Editorials*  
**[Sparing of Severe Covid-19 in Vaccinated Adolescents](#)**  
K.M. Edwards

**[Audio Interview: Understanding the Omicron Variant of SARS-CoV-2](#)**  
E.J. Rubin, L.R. Baden, and S. Morrissey

**njp Vaccines**  
<https://www.nature.com/npjvaccines/>  
[Accessed 26 Feb 2022]  
**[An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission](#)**  
Kairat Tabynov, Nurkeldi Turebekov, Kaissar Tabynov  
Article Open Access 23 Feb 2022

**[The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England](#)**  
Joshua Nealon, Daniel Modin, Tor Biering-Sørensen  
Article Open Access 23 Feb 2022

**Pediatrics**  
Volume 149, Issue 2, February 1, 2022  
<https://pediatrics.aappublications.org/>  
[Reviewed earlier]

## **PharmacoEconomics**

Volume 40, issue 2, February 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-2>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 26 Feb 2022)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 26 Feb 2022)

[No new digest content identified]

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 26 Feb 2022)

### **Vaccine equity: A fundamental imperative in the fight against COVID-19**

The PLOS Medicine Editors

Editorial | published 22 Feb 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003948>

### **Learning from the COVID-19 pandemic to strengthen routine immunization systems**

Kate Causey, Jonathan F. Mosser

Perspective | published 22 Feb 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003934>

### **First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales**

Steven Kerr, Mark Joy, Fatemeh Torabi, Stuart Bedston, Ashley Akbari, Utkarsh Agrawal, Jillian Beggs, Declan Bradley, Antony Chuter, Annemarie B. Docherty, David Ford, Richard Hobbs, Srinivasa Vittal Katikireddi, Emily Lowthian, Simon de Lusignan, Ronan Lyons, James Marple, Colin McCowan, Dylan McGagh, Jim McMenamin, Emily Moore, Josephine-L. K. Murray, Rhiannon K. Owen, Jiafeng Pan, Lewis Ritchie, Syed Ahmar Shah, Ting Shi, Sarah Stock, Ruby S. M. Tsang, Eleftheria Vasileiou, Mark Woolhouse, Colin R. Simpson, Chris Robertson, Aziz Sheikh

Research Article | published 22 Feb 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003927>

### **Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data**

Fiona McQuaid, Rachel Mulholland, Yuma Sangpang Rai, Utkarsh Agrawal, Helen Bedford, J. Claire Cameron, Cheryl Gibbons, Partho Roy, Aziz Sheikh, Ting Shi, Colin R. Simpson, Judith Tait, Elise Tessier, Steve Turner, Jaime Villacampa Ortega, Joanne White, Rachael Wood

Research Article | published 22 Feb 2022 PLOS Medicine  
<https://doi.org/10.1371/journal.pmed.1003916>

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 26 Feb 2022)

[No new digest content identified]

**PLoS One**

<http://www.plosone.org/>

[Accessed 26 Feb 2022]

*Research Article*

**[Qualitative systems mapping for complex public health problems: A practical guide](#)**

Anneleen Kiekens, Bernadette Dierckx de Casterlé, Anne-Mieke Vandamme

Research Article | published 25 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0264463>

**[Factors influencing COVID-19 vaccine uptake among adults in Nigeria](#)**

Halimat Adedeji-Adenola, Olubusola A. Olugbake, Shakirat A. Adeosun

Research Article | published 24 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0264371>

**[Measles containing vaccine coverage and factors associated with its uptake among children aged 24–59 months in Cherangany Sub County, Trans Nzoia County, Kenya](#)**

Stella Mamuti, Collins Tabu, Irene Marete, Davies Opili, Rose Jalang'o, Ahmed Abade

Research Article | published 23 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263780>

**[Estimated impact of the 2020 economic downturn on under-5 mortality for 129 countries](#)**

Marcelo Cardona, Joseph Millward, Alison Gemmill, Katelyn Jison Yoo, David M. Bishai

Research Article | published 23 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263245>

**[Determinants of acceptance of Coronavirus disease-2019 \(COVID-19\) vaccine among Lebanese health care workers using health belief model](#)**

Dalal Youssef, Linda Abou-Abbas, Atika Berry, Janet Youssef, Hamad Hassan

Research Article | published 22 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0264128>

**[Media attention and Vaccine Hesitancy: Examining the mediating effects of Fear of COVID-19 and the moderating role of Trust in leadership](#)**

Lulin Zhou, Sabina Ampon-Wireko, Xinglong Xu, Prince Edwudzie Quansah, Ebenezer Larnyo

Research Article | published 18 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263610>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 26 Feb 2022]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**

February 01, 2022; vol. 119 no. 5

<https://www.pnas.org/content/119/5>

[New issue; No digest content identified]

**Prehospital & Disaster Medicine**

Volume 37 - Issue 1 - February 2022

<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

**Preventive Medicine**

Volume 155 February 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/155/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

23 February 2022 Volume 289 Issue 1969

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

**Public Health**

Volume 203 Pages 1-130 (February 2022)

<https://www.sciencedirect.com/journal/public-health/vol/203/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 137 Issue 1, January/February 2022

<https://journals.sagepub.com/toc/phrg/137/1>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 32 Issue 3, February 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

## **Research Ethics**

Volume 18 Issue 1, January 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 26 Feb 2022]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

[No new digest content identified]

## **Risk Analysis**

Volume 42, Issue 1 January 2022

<https://onlinelibrary.wiley.com/toc/15396924/current>

***Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus in Post-Pandemic Era***

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 26 Feb 2022]

*Original Research*

**Understanding the Facilitators and Barriers to COVID-19 Vaccine Uptake Among Teachers in the Sagnarigu Municipality of Northern Ghana: A Cross-Sectional Study**

Dubik SD

Published Date: 24 February 2022

## **Science**

Volume 375| Issue 6583| 25 Feb 2022

<https://www.science.org/toc/science/current>

*Policy Forum*

**Streamlining ethics review for international health research**

BY Mark A. Rothstein et al  
24 Feb 2022: 825-826  
Single-site review means protection and efficiency

*Research Articles*

**A unified genealogy of modern and ancient genomes**

BY Anthony Wilder Wohns, et al.  
25 Feb 2022  
A genealogy of modern and ancient genomes provides insight into human history and evolution.

**Science Translational Medicine**

Volume 14| Issue 633| 23 Feb 2022  
<https://www.science.org/toc/stm/current>

*Research Articles*

**Predicting the mutational drivers of future SARS-CoV-2 variants of concern**

BY M. Cyrus Maher, et al.  
23 Feb 2022  
*Open Access*

Simple epidemiologic metrics accurately predict which mutations in the SARS-CoV-2 genome will increase in frequency over the coming months.

**Social Science & Medicine**

Volume 292 January 2022  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/292/suppl/C>  
[Reviewed earlier]

**Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 26 Feb 2022]  
[No new digest content identified]

**Theoretical Medicine and Bioethics**

Volume 42, issue 3-4, August 2021  
<https://link.springer.com/journal/11017/volumes-and-issues/42-3>  
***Special Issue: A plea for an experimental philosophy of medicine***  
[Reviewed earlier]

**Travel Medicine and Infectious Diseases**

Volume 45 January–February 2022  
<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/45/suppl/C>  
[Reviewed earlier]

**Tropical Medicine & International Health**

Volume 27, Issue 2 Pages: i-iv, 121-216 February 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

**Vaccine**

Volume 40, Issue 6 Pages 833-966 (7 February 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/6>*Short communication Open access***[Understanding COVID-19 vaccination willingness among youth: A survey study in the Netherlands](#)**

Saskia Euser, Floor M. Kroese, Mare Derkx, Marijn de Bruin

Pages 833-836

*Short communication Full text access***[COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid](#)**

Brigham Walker, Andrew Anderson, Charles Stoecker, Yixue Shao, ... Kevin Callison

Pages 837-840

*Research article Full text access***[Factors associated with COVID-19 vaccination intentions among adults in the deep South](#)**

Casey L. Daniel, Jacob Williams, Rachel Legg, Chelsea McGowen, Jesse Stutzman

Pages 841-853

*Research article Abstract only***[Effect of the framing of HPV vaccination on parents' willingness to accept an HPV vaccine](#)**

Zhuoying Huang, Mengdi Ji, Jia Ren, Xiaodong Sun, ... Abram L. Wagner

Pages 897-903

*Research article Open access***[Improving knowledge and trust in vaccines: A survey-based assessment of the potential of the European Union Clinical Trial Regulation No 536/2014 plain language summary to increase health literacy](#)**

Michael Penlington, Philibert Goulet, Beth Metcalfe

Pages 924-933

*Research article Open access***[COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey](#)**

Gilla K. Shapiro, Nisha Gottfredson, Julie Leask, Kerrie Wiley, ... Noel T. Brewer

Pages 945-952

*Research article Abstract only***[Vaccine misinformation types and properties in Russian troll tweets](#)**

Echo L. Warner, Juliana L. Barbat, Kaylin L. Duncan, Kun Yan, Stephen A. Rains

Pages 953-960

## **Value in Health**

February 2022 Volume 25 Issue 2 p161-320  
<https://www.valueinhealthjournal.com/current>  
[Reviewed earlier]

:::::::

:::::::

## **Pre-Print Servers**

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 26 Feb 2022]

*Research Article metrics*

Revised

### **Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019** [version 2; peer review: 1 approved, 1 approved with reservations]

Sydney Rosen, Brooke Nichols, Teresa Guthrie, Mariet Benade, Salome Kuchukhidze, Lawrence Long  
Peer Reviewers Ingrid Eshun-Wilson; Michael J. Vinikoor

Funder

NIH

LATEST VERSION PUBLISHED 25 Feb 2022

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

### **Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine**

Tal Patalon, Yaki Saciuk, Asaf Peretz, Galit Perez, Yoav Lurie, Yasmin Maor, Sivan Gazit  
medRxiv 2022.02.25.22271494; doi: <https://doi.org/10.1101/2022.02.25.22271494>

### **The effect of job strain and worksite social support on reported side effects of COVID-19 vaccine: a prospective study of employees in Japan**

Natsu Sasaki, Reiko Kuroda, Kanami Tsuno, Kotaro Imamura, Norito Kawakami  
medRxiv 2022.02.24.22271484; doi: <https://doi.org/10.1101/2022.02.24.22271484>

### **Booster protection against Omicron infection in a highly vaccinated cohort**

Caroline Tai, Lisa L Maragakis, Sarah Connelly, John DiFiori, Leroy Sims, Eleanor Adams, Deverick Anderson, Michael Merson, David Ho, Yonatan Grad, Christina DeFilippo Mack

medRxiv 2022.02.24.22271347; doi: <https://doi.org/10.1101/2022.02.24.22271347>

**Rapid genome surveillance of SARS-CoV-2 and study of risk factors using shipping container laboratories and portable DNA sequencing technology**

SARA FARAH BILOOEI, Dejana Jovicevic, Arash Iranzadeh, Cynthia Mpofu, Ivan Muscat, Anthony Thomas, Helene Steiner, Thomas Meany

medRxiv 2022.02.25.22271277; doi: <https://doi.org/10.1101/2022.02.25.22271277>

**Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States**

Manuela Di Fusco, Kinga Marczell, Kristen A Deger, Mary M Moran, Timothy L Wiemken, Alejandro Cane, Solene de Boisvilliers, Jingyan Yang, Shailja Vaghela, Julie Roiz

medRxiv 2022.02.24.22271478; doi: <https://doi.org/10.1101/2022.02.24.22271478>

**At least three doses of leading vaccines essential for neutralisation of SARS-CoV-2 Omicron variant**

Nagendrakumar B Singanallur, Petrus Jansen van Vuren, Alexander James McAuley, Matthew P Bruce, Michael J Kuiper, Stella May Gwini, Shane Riddell, Sarah Goldie, Trevor W Drew, Kim Rebecca Blasdell, Mary Tachedjian, Shruthi Mangalaganesh, Simran Chahal, Leon Caly, Julian D Druce, Jennifer A Juno, Stephen Kent, Adam K Wheatley, Seshadri S Vasan

medRxiv 2022.02.20.22271237; doi: <https://doi.org/10.1101/2022.02.20.22271237>

**Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population**

Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Yumiko Saga, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Hideki Niimi, Yoshihiro Yamamoto

medRxiv 2022.02.23.22271433; doi: <https://doi.org/10.1101/2022.02.23.22271433>

**Bibliometric study of preclinical, clinical, and public health systematic reviews and meta-analyses in Ethiopia: systematically mapping publication outputs, authors collaboration networks, trending research topics, and influential articles**

Tesfa Dejenie Habtewold, Nigussie Tadesse Sharew, Aklilu Endalamaw, Henok Mulugeta, Getenet Dessie, Nigus Gebremedhin Asefa, Getachew Mulu Kassa, Wubet Alebachew Bayih, Mulugeta Molla Birhanu, Andreas A. Teferra, Abera Kenay Tura, Balewgize Sileshi Tegegne, Sisay Mulugeta Alemu

medRxiv 2022.02.24.22271416; doi: <https://doi.org/10.1101/2022.02.24.22271416>

**The impact of COVID passport mandates on the number of cases of and hospitalizations with COVID-19 in the UK: a difference-in-differences analysis**

Kim López-Güell, Albert Prats-Uribe, Martí Catalá, Clara Prats, Jotun Hein, DANIEL PRIETO-ALHAMBRA

medRxiv 2022.02.24.22271325; doi: <https://doi.org/10.1101/2022.02.24.22271325>

**Dynamics of the Delta and Omicron variants of SARS-CoV-2 in the United States: the battle of supremacy in the presence of vaccination, mask usage and antiviral treatment**

Calistus N. Ngonghala, Hemaho B. Taboe, Abba B. Gumel

medRxiv 2022.02.23.22271394; doi: <https://doi.org/10.1101/2022.02.23.22271394>

**When mistrust in the government and scientists reinforce social inequalities in vaccination against Covid-19**

Nathalie Bajos, Alexis Spire, Léna Silberzan, Antoine Sireyjol, Florence Jusot, Laurence Meyer, Jeanna-Eve Franck, Josiane Warszawski, the EpiCov study group  
medRxiv 2022.02.23.22271397; doi: <https://doi.org/10.1101/2022.02.23.22271397>

**Estimating the impact of implementation and timing of COVID-19 vaccination programme in Brazil: a counterfactual analysis**

Leonardo Souto Ferreira, Flavia Maria Darcie Marquitti, Rafael Lopes Paixão da Silva, Marcelo Eduardo Borges, Marcelo Ferreira da Costa Gomes, Oswaldo Gonçruz Cruz, Roberto André Kraenkel, Renato Mendes Coutinho, Paulo Inácio Prado, Leonardo Soares Bastos  
medRxiv 2021.12.24.21268384; doi: <https://doi.org/10.1101/2021.12.24.21268384>

**SARS-CoV-2 seroprevalence, vaccination, and hesitancy in agricultural workers in Guatemala**

Diva M. Calvimontes, Lyndsay Krisher, Alex Cruz-Aguilar, Daniel Pilloni-Alessio, Luis E. Crisostomo-Cal, Edgar A. Castañeda-Sosa, Jaime Butler-Dawson, Daniel Olson, Lee S. Newman, Edwin J. Asturias  
medRxiv 2022.02.22.22270907; doi: <https://doi.org/10.1101/2022.02.22.22270907>

**An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile**

Jorge A Soto, Felipe Melo-González, Cristián Gutierrez-Vera, Bárbara M Schultz, Roslye V Berrios-Rojas, Daniela Rivera-Pérez, Alejandro Piña-Iturbe, Guillermo Hoppe-Elsholz, Luisa F Duarte, Yaneisi Vázquez, Daniela Moreno-Tapia, Mariana Ríos, Pablo A Palacios, Richard Garcia-Betancourt, Álvaro Santibañez, Constanza Mendez, Benjamín Diethelm-Varela, Patricio Astudillo, Mario Calvo, Antonio Cárdenas, Marcela González, Macarena Goldsack, Valentina Gutiérrez, Marcela Potin, Andrea Schilling, Lorena I Tapia, Loreto Twele, Rodolfo Villena, Alba Grifoni, Alessandro Sette, Daniela Weiskopf, Rodrigo A Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Mónica Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Angello Retamal-Díaz, Nathalia Muñoz-Jofré, PedCoronaVac03CL Study Group, Xing Meng, Qianqian Xin, Eduardo Alarcón-Bustamante, José V González-Aramundiz, Nicole Le Corre, María Javiera Álvarez, Pablo A González, Katia Abarca, Cecilia Perret, Leandro J Carreño, Alexis M Kalergis, Susan M Bueno  
medRxiv 2022.02.15.22270973; doi: <https://doi.org/10.1101/2022.02.15.22270973>

**Community-based Case Studies of Vaccine Hesitancy and the COVID-19 Response in South Africa; The VaxScenes Study**

Charles Shey Wiysonge, Nancy Coulson, Nirvana Pillay, Sara Cooper, Candice Groenewald, Zaynab Essack, Saahier Parker, Gregory Houston, Jane Simmonds, Anelisa Jaca, Muyunda Mutemwa, Patrick DMC Katoto, Heidi van Rooyen  
medRxiv 2022.02.21.22271272; doi: <https://doi.org/10.1101/2022.02.21.22271272>

**Anti-SARS-CoV-2 IgG antibodies after recovery from COVID-19 or vaccination in Libyan population: comparison of four vaccines**

Fawzi Ebrahim, Salah Tabal, Yosra Lamami, Inas M Alhudiri, Salah Edin El Meshri, Samira M Al Dwigen, Ramadan Arfa, Asma Alboeshi, Hafsa A. Alemam, Fauzia Abuhtna, Rabeeah Altrhouni, Mohamed B Milad, Nada A Elgriw, Mahmoud A Ruua, Zakarya Abusrewil, Warda Harroush, Mwada Jallul, Fouziyah S Ali, Farag Eltaeb, Adam Elzaghi  
medRxiv 2022.02.18.22271130; doi: <https://doi.org/10.1101/2022.02.18.22271130>

**Wellcome Open Research** [to 26 Feb 2022]  
<https://wellcomeopenresearch.org/browse/articles>  
[Accessed 26 Feb 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

*Research Article metrics*

Revised

[\*\*Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data\*\*](#) [version 2; peer review: 1 approved, 1 approved with reservations]

John Ojal, Samuel P. C. Brand, Vincent Were, Emelda A. Okiro, Ivy K. Kombe, Caroline Mburu, Rabia Aziza, Morris Ogero, Ambrose Agweyu, George M. Warimwe, Sophie Uyoga, Ifedayo M. O. Adetifa, J. Anthony G. Scott, Edward Otieno, Lynette I. Ochola-Oyier, Charles N. Agoti, Kadondi Kasera, Patrick Amoth, Mercy Mwangangi, Rashid Aman, Wangari Ng'ang'a, Benjamin Tsofa, Philip Bejon, Edwine Barasa, Matt J. Keeling, D. James Nokes

Peer Reviewers Mark Kimathi; Amy Wesolowski

Funders

Wellcome Trust

National Institute for Health Research

Medical Research Council

Foreign, Commonwealth and Development Office

LATEST VERSION PUBLISHED 25 Feb 2022

*Research Article metrics*

Revised

[\*\*Individual-level variations in malaria susceptibility and acquisition of clinical protection\*\*](#)

[version 3; peer review: 1 approved, 1 approved with reservations]

John Joseph Valletta, John W.G. Addy, Adam J. Reid, Francis M. Ndungu, Yaw Bediako, Jedida Mwacharo, Khadija Said, Jennifer Musyoki, Joyce Mwongeli Ngoi, Joshua Wambua, Edward Otieno, Matt Berriman, Philip Bejon, Kevin Marsh, Jean Langhorne, Chris I. Newbold, Mario Recker

Peer Reviewers Lucy C. Okell; Wendy Prudhomme-O'Meara and Christine Markwalter

Funders

Wellcome Trust

Cancer Research UK

Medical Research Council

Crick Africa Network

LATEST VERSION PUBLISHED 25 Feb 2022

\*

\*

\*

\*

## **Think Tanks**

**Brookings**

<http://www.brookings.edu/>

Accessed 26 Feb 2022

Upcoming Event

### **Public health in Africa: Ensuring equal access and self-sufficiency**

Feb 28 9:30 AM - 11:00 AM EST

Online Only

Health Care Policy

### **5 building blocks to help achieve greater health equity**

Stuart M. Butler and Nehath Sheriff

Tuesday, February 22, 2022

**Center for Global Development** [to 26 Feb 2022]

<https://www.cgdev.org/>

Accessed 26 Feb 2022

### **Operationalizing the African Medicines Agency: The Strategic Design of a Regional Platform for Medicines Regulation**

Event 2/24/22

As of November 5, 2021, the African Union signed into force its second specialized health agency: the African Medicines Agency (AMA). More than two years after its introduction, the [AMA treaty](#) has now been ratified by 17 African Union member countries – two more than was required – and has been signed by many more, making it the latest regional partnership to strengthen capacity for medicines regulation and facilitate regulatory harmonization across the African continent in order to improve access to safe, effective, and quality-assured medicines. With high-level support secured, attention now must shift to strategic questions of how to operationalize the AMA and set it up for success.

February 16, 2022

### **Social Protection in the COVID-19 Pandemic: Lessons from South Africa**

South Africa responded to the stresses of the COVID-19 pandemic and lockdown using a combination of existing social protection programmes, unemployment insurance, and additional measures to support those most affected. This paper reviews policies and implementation with the objective of highlighting lessons for the global community, including on the use of digital mechanisms.

Lena Gronbach , Jeremy Seekings and Vayda Megannon

**Chatham House** [to 26 Feb 2022]

<https://www.chathamhouse.org/>

Accessed 26 Feb 2022

### **Explainer The next pandemic – when could it be?**

How, when, and where could a new pandemic occur, what measures might prevent such an event, and is the world well-prepared if it does happen?

23 February 2022

**CSIS**

<https://www.csis.org/>

Accessed 26 Feb 2022

Upcoming Event

## **Overcoming Gender-Related Barriers to Immunization Services**

March 8, 2022

### **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

Accessed 26 Feb 2022

[No new digest content identified]

**Rand** [to 26 Feb 2022]

<https://www.rand.org/pubs.html>

*Reports, Selected Journal Articles*

*Report*

### **Incorporating Complementary and Integrative Health Providers in the Public Health Pandemic Response: Lessons from COVID-19 and Recommendations for the Future from a Multidisciplinary Expert Panel**

Complementary and integrative health providers have been an underutilized public health asset in the response to the COVID-19 pandemic. This report seeks to inform how they can be better integrated into future responses to public health emergencies.

Feb 17, 2022

Ian D. Coulter, Margaret D. Whitley, Raheleh Khorsan, Patricia M. Herman

*Report*

### **COVID-19 Genomics UK (COG-UK) Consortium: Final Report**

RAND Europe evaluated how the COVID-19 Genomics UK (COG-UK) Consortium contributed to the pandemic response in the United Kingdom and examined the role of pathogen genomics research and sequencing networks in pandemic response.

Feb 15, 2022

Sonja Marjanovic, Robert J. Romanelli, Gemma-Claire Ali, Brandi Leach, Margaretha Bonsu, Daniela Rodriguez-Rincon, Tom Ling

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

*Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

:::::::

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*